{"meta":{"page":1,"per_page":50,"max_per_page":100,"total":1073,"total_is_capped":false,"direct_labels_cover":5,"predictions_cover":1073,"direct_label_status":"direct model label, unvalidated","prediction_status":"machine_predicted_unvalidated (Codex and Gemma teacher distillation)","score_status":"score_only:v0-immature-baseline (scores rank; they never assert a category)","snapshot":{"source":"OpenAlex, pinned release, all 482 partitions","release":"2026-06-24","frame_built":"2026-07-12"},"query_hash":"4bcee9d87cb6","filters":{"topic":"Colorectal Cancer Treatments and Studies"}},"results":[{"id":"W2155311724","doi":"10.1056/nejmoa0804385","title":"<i>K-ras</i> Mutations and Benefit from Cetuximab in Advanced Colorectal Cancer","year":2008,"lang":"en","type":"article","venue":"New England Journal of Medicine","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":3597,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Ontario Institute for Cancer Research; Ottawa Hospital; University of Ottawa","funders":"","keywords":"Cetuximab; Medicine; Colorectal cancer; Hazard ratio; Internal medicine; Oncology; Progression-free survival; Cancer; Exon; Confidence interval; Chemotherapy; Gene; Biology; Genetics","retraction":null,"screen_n_in":null,"score":{"opus":0.01824294315453895,"gpt":0.2893600566152159,"spread":0.2711171134606769,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001020425,0.0001307017,0.0005396978,0.0001381489,0.00006342884,0.00000251099,0.0000393555,0.00003786218,0.0001659882],"category_scores_gemma":[0.0001158925,0.00008292755,0.00004043533,0.0001670005,0.0001282541,0.00007561382,0.00001451405,0.0002138512,7.679621e-7],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0001096829,"about_ca_system_score_gemma":0.0001402952,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001376,"about_ca_topic_score_gemma":0.001619408,"domain_scores_codex":[0.9990705,0.00001441071,0.0003695546,0.000124147,0.0002737759,0.0001476232],"domain_scores_gemma":[0.9992803,0.0001873408,0.0001556278,0.00005655568,0.0001281861,0.0001920304],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.005550515,0.0002292968,0.616445,0.00002441131,0.0003872183,0.001767625,0.01144196,0.00008401259,0.007047437,0.00004224812,0.002307376,0.3546729],"study_design_scores_gemma":[0.0947629,0.002984405,0.8856574,0.0005378267,0.0002844933,0.001258145,0.0006408482,0.00003553672,0.0008107606,0.0008820454,0.0120368,0.0001088013],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9727131,0.01817491,0.00001761805,0.007420511,0.0003517877,0.0001320228,0.00001025879,0.000007016155,0.001172827],"genre_scores_gemma":[0.9890564,0.008508525,0.0004447516,0.0003951939,0.001257052,0.000005835369,0.000006985642,0.0000106066,0.000314645],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.3545641,"threshold_uncertainty_score":0.3381687,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2314927739","doi":"10.1056/nejm200009283431302","title":"Irinotecan plus Fluorouracil and Leucovorin for Metastatic Colorectal Cancer","year":2000,"lang":"en","type":"article","venue":"New England Journal of Medicine","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":3010,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Ottawa Regional Cancer Foundation","funders":"","keywords":"Irinotecan; Medicine; Fluorouracil; Bolus (digestion); Colorectal cancer; Chemotherapy; Internal medicine; Gastroenterology; Surgery; Cancer","retraction":null,"screen_n_in":null,"score":{"opus":0.03290594841131935,"gpt":0.3246259538774529,"spread":0.2917200054661335,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003122989,0.0001602954,0.0006548957,0.00009405863,0.00007698766,0.000007346593,0.00004775034,0.000029249,0.0007488463],"category_scores_gemma":[0.0001343894,0.00009325441,0.00007617271,0.0001039329,0.0001073381,0.00006138173,0.000008707882,0.0001626356,0.000001188732],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0001456772,"about_ca_system_score_gemma":0.0002655981,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0004832681,"about_ca_topic_score_gemma":0.0003675367,"domain_scores_codex":[0.9989747,0.00002779997,0.0003814685,0.0001293962,0.0002882557,0.0001983586],"domain_scores_gemma":[0.9991522,0.0002134116,0.0001398578,0.00006341769,0.0001598949,0.0002711822],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.007626735,0.0000745804,0.003602612,0.00007909524,0.0005872928,0.0001992513,0.002420679,0.00003009982,0.0009695038,0.00003266228,0.007385768,0.9769917],"study_design_scores_gemma":[0.2858527,0.03182906,0.08219521,0.001329138,0.003791721,0.005778461,0.001157071,0.0004331065,0.001968325,0.001168975,0.5841178,0.0003784887],"study_design_candidate":"design_other","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9690166,0.01573678,0.000103787,0.01278294,0.000349007,0.0003200852,0.00001040387,0.00001043931,0.001670026],"genre_scores_gemma":[0.9876951,0.005638243,0.0008421773,0.0004685362,0.00255673,0.00001534256,0.000003651877,0.000016436,0.002763806],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.9766132,"threshold_uncertainty_score":0.8199341,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2143743735","doi":"10.1200/jco.2007.14.9930","title":"Bevacizumab in Combination With Oxaliplatin-Based Chemotherapy As First-Line Therapy in Metastatic Colorectal Cancer: A Randomized Phase III Study","year":2008,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":2963,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"CancerCare Manitoba","funders":"","keywords":"Bevacizumab; Medicine; Oxaliplatin; FOLFOX; Folinic acid; Internal medicine; Colorectal cancer; Oncology; Capecitabine; Clinical endpoint; Chemotherapy; Placebo; Hazard ratio; Progression-free survival; Surgery; Randomized controlled trial; Cancer; Confidence interval; Pathology","retraction":null,"screen_n_in":null,"score":{"opus":0.1003262096290122,"gpt":0.4668804551886769,"spread":0.3665542455596647,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002808337,0.0002261233,0.003339486,0.000286936,0.00006611537,0.000005348592,0.00009952614,0.0001238547,0.0001844092],"category_scores_gemma":[0.001021496,0.0001323439,0.0003481318,0.0003948616,0.0003203796,0.00007802239,0.00001270611,0.0006461031,0.000001520365],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00046775,"about_ca_system_score_gemma":0.002112714,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0007931033,"about_ca_topic_score_gemma":0.004375896,"domain_scores_codex":[0.9959361,0.0007750411,0.002351102,0.0002396651,0.0004640964,0.0002340106],"domain_scores_gemma":[0.9944037,0.003578772,0.00138338,0.0001087347,0.0003702618,0.0001551568],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.7567224,0.02815787,0.1437737,0.00001069503,0.001226462,0.002554791,0.002226249,0.0001973864,0.00001776878,0.000005941728,0.00007290138,0.06503387],"study_design_scores_gemma":[0.7232818,0.09068837,0.183564,0.00009112885,0.0002760773,0.0001363063,0.0003486132,0.0008438114,0.00006469574,0.00007941967,0.0005225685,0.0001032308],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9894973,0.001072731,0.0000287632,0.006736963,0.000280019,0.002021522,0.000002511772,0.000008942112,0.0003512716],"genre_scores_gemma":[0.9935449,0.004396458,0.0004809159,0.001158344,0.0001390117,0.0001948652,0.000003206598,0.00001997953,0.00006231182],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.06493064,"threshold_uncertainty_score":0.5396829,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2115790682","doi":"10.1056/nejmoa071834","title":"Cetuximab for the Treatment of Colorectal Cancer","year":2007,"lang":"en","type":"article","venue":"New England Journal of Medicine","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":1806,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Lakeridge Health; Sunnybrook Health Science Centre; Queen's University; Ottawa Hospital; St. Boniface Hospital; University of Ottawa","funders":"","keywords":"Cetuximab; Medicine; Irinotecan; Hazard ratio; Internal medicine; Colorectal cancer; Oxaliplatin; Oncology; Confidence interval; Cancer","retraction":null,"screen_n_in":null,"score":{"opus":0.03249577843555444,"gpt":0.3453493300105736,"spread":0.3128535515750191,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000387703,0.0001177654,0.0005144509,0.0000845694,0.00005786389,0.000001804782,0.00005111052,0.00003046007,0.0001138903],"category_scores_gemma":[0.0001052236,0.00004891765,0.0001361907,0.0001123239,0.0001167161,0.00001951618,0.000004305905,0.00006673689,2.442372e-7],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0001640079,"about_ca_system_score_gemma":0.0001620796,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0003833091,"about_ca_topic_score_gemma":0.0005838384,"domain_scores_codex":[0.9990806,0.0000106154,0.0004042008,0.00007283688,0.0002704718,0.0001613036],"domain_scores_gemma":[0.9986649,0.0006187345,0.0002515974,0.0000751265,0.0002595706,0.0001301047],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.01372233,0.0003865798,0.02834624,0.00003434885,0.001223395,0.00009331878,0.005190675,0.000009789384,0.003290701,0.000072909,0.005511265,0.9421185],"study_design_scores_gemma":[0.1840457,0.05159247,0.1833508,0.0003914691,0.002800317,0.0007183183,0.001658018,0.00004338781,0.01360314,0.0002514492,0.5614328,0.0001121058],"study_design_candidate":"design_other","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9420724,0.04081362,0.0007691094,0.01337798,0.001157535,0.0004707474,0.000008150772,0.000005422375,0.001325033],"genre_scores_gemma":[0.9867579,0.008202136,0.0003658236,0.0001673991,0.003797863,0.000007485604,0.000001600061,0.00001010118,0.0006896854],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.9420063,"threshold_uncertainty_score":0.1994804,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2146161922","doi":"10.1056/nejmoa043116","title":"Capecitabine as Adjuvant Treatment for Stage III Colon Cancer","year":2005,"lang":"en","type":"article","venue":"New England Journal of Medicine","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":1247,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Ottawa Regional Cancer Foundation","funders":"","keywords":"Capecitabine; Medicine; Fluorouracil; Hazard ratio; Internal medicine; Colorectal cancer; Regimen; Clinical endpoint; Bolus (digestion); Adverse effect; Gastroenterology; Oncology; Adjuvant; Surgery; Confidence interval; Chemotherapy; Cancer; Randomized controlled trial","retraction":null,"screen_n_in":null,"score":{"opus":0.03438742929994011,"gpt":0.3506999515904616,"spread":0.3163125222905215,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0002271574,0.000199442,0.0007943979,0.0001269589,0.00007824393,0.000005086044,0.00005549043,0.00004521084,0.000979],"category_scores_gemma":[0.0001130808,0.0001065865,0.0001344337,0.00009766616,0.00006686139,0.00005844039,0.000009878046,0.0001166232,0.000003468978],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0004936669,"about_ca_system_score_gemma":0.0003768479,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0008772097,"about_ca_topic_score_gemma":0.001433846,"domain_scores_codex":[0.9987944,0.00001949015,0.0004741551,0.0001418986,0.0003347791,0.0002352955],"domain_scores_gemma":[0.9988949,0.0001592673,0.0002601774,0.0001138133,0.0002557298,0.000316146],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.01132988,0.0003451368,0.004454191,0.0000414091,0.0009334405,0.0002505373,0.003881773,0.00006084967,0.002847437,0.0001060637,0.02537245,0.9503768],"study_design_scores_gemma":[0.15184,0.01710034,0.00510745,0.0003309035,0.0009687645,0.0004441699,0.0004799426,0.00005792834,0.001821854,0.00006543905,0.8216816,0.0001015682],"study_design_candidate":"design_other","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.8943677,0.03482914,0.0001573846,0.06435757,0.0009165224,0.0006478686,0.00002230388,0.00001777927,0.004683766],"genre_scores_gemma":[0.9578223,0.008281481,0.000610773,0.001143522,0.009912061,0.00002945015,0.000009433806,0.00002161439,0.02216942],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.9502752,"threshold_uncertainty_score":0.9999343,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2121847974","doi":"10.1016/s1470-2045(15)70127-0","title":"Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): a randomised, double-blind, multicentre, phase 3 study","year":2015,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":955,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Eli Lilly (Canada)","funders":"Eli Lilly and Company","keywords":"Bevacizumab; FOLFIRI; Ramucirumab; Medicine; Oxaliplatin; Oncology; Internal medicine; Colorectal cancer; Second-line therapy; Placebo; Chemotherapy; Overall survival; Cancer; Pathology","retraction":null,"screen_n_in":null,"score":{"opus":0.09086894514201639,"gpt":0.3537783983077336,"spread":0.2629094531657172,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000459883,0.0003986629,0.001198616,0.0001837478,0.0001114915,0.0000318239,0.0001111975,0.00006733317,0.00004965108],"category_scores_gemma":[0.00004839051,0.0001919576,0.00003070219,0.0004020326,0.0002194214,0.000146025,0.00006991912,0.0003031367,0.000001479491],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0004734641,"about_ca_system_score_gemma":0.0002856858,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0002046667,"about_ca_topic_score_gemma":0.03123084,"domain_scores_codex":[0.9979714,0.0002627322,0.0003807555,0.0004861631,0.0004067153,0.000492264],"domain_scores_gemma":[0.9987286,0.000394301,0.0002531028,0.0002860781,0.0002007328,0.000137186],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.6018692,0.004607948,0.3820623,0.00005682293,0.0004390175,0.0005178199,0.008939328,0.00002748949,0.000002343682,0.000001073553,0.000007112916,0.001469523],"study_design_scores_gemma":[0.6475266,0.05345634,0.2960895,0.00008615061,0.0003307181,0.00003776249,0.001871094,0.0002378239,0.0001261222,0.000003146347,0.00005013684,0.0001845656],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9888409,0.0005595019,0.000002791737,0.0008455443,0.00008087163,0.009438425,0.00002527852,0.0000415717,0.00016507],"genre_scores_gemma":[0.9965404,0.00006132277,0.0002687185,0.00007419139,0.00005921815,0.0028275,0.000059529,0.00004356354,0.00006552642],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.08597283,"threshold_uncertainty_score":0.9864467,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2712978371","doi":"10.1001/jama.2017.7105","title":"Effect of First-Line Chemotherapy Combined With Cetuximab or Bevacizumab on Overall Survival in Patients With <i>KRAS</i> Wild-Type Advanced or Metastatic Colorectal Cancer","year":2017,"lang":"en","type":"article","venue":"JAMA","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":893,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":true},"ca_institutions":"University of Toronto; Sunnybrook Health Science Centre","funders":"National Center for Advancing Translational Sciences; National Cancer Institute","keywords":"Medicine; Bevacizumab; Cetuximab; FOLFIRI; Irinotecan; Regimen; KRAS; Internal medicine; Oncology; Oxaliplatin; Colorectal cancer; Chemotherapy regimen; Chemotherapy; Cancer","retraction":null,"screen_n_in":null,"score":{"opus":0.01304249158422767,"gpt":0.2971890219946865,"spread":0.2841465304104588,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001218948,0.00033652,0.0009567981,0.00007085699,0.000160842,0.00002834219,0.0001335122,0.00005328489,0.0001337998],"category_scores_gemma":[0.0001738221,0.0001616801,0.00005891921,0.0001579697,0.0001427113,0.0001397984,0.00003986147,0.0001659367,0.000002447806],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0002592258,"about_ca_system_score_gemma":0.0001421454,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0005337353,"about_ca_topic_score_gemma":0.00643437,"domain_scores_codex":[0.9985908,0.00005371957,0.0002500033,0.000360709,0.0004386628,0.0003061325],"domain_scores_gemma":[0.9988034,0.000251998,0.0002747524,0.0003768995,0.0002076387,0.00008526399],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.458234,0.001241764,0.4951818,0.000288507,0.0007390481,0.000105935,0.0003700817,0.00004398133,0.00004064258,0.000005138609,0.0001242507,0.04362493],"study_design_scores_gemma":[0.1238891,0.1032851,0.7653778,0.0007928949,0.0003323743,0.000003688865,0.00002907489,0.00007719689,0.005309815,0.000004048371,0.0006521074,0.0002467833],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9964119,0.0001000076,0.000001512287,0.0007738328,0.000169258,0.0016405,0.00006565791,0.00002658508,0.0008107781],"genre_scores_gemma":[0.9985335,0.0002263372,0.0001361629,0.0001804729,0.00004384734,0.0002027727,0.0000351803,0.00004596065,0.0005956967],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.3343448,"threshold_uncertainty_score":0.6593125,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2132545630","doi":"10.1200/jco.2007.11.3357","title":"Randomized, Controlled Trial of Irinotecan Plus Infusional, Bolus, or Oral Fluoropyrimidines in First-Line Treatment of Metastatic Colorectal Cancer: Results From the BICC-C Study","year":2007,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":857,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Lakeridge Health","funders":"","keywords":"FOLFIRI; Medicine; Irinotecan; Bevacizumab; Internal medicine; Clinical endpoint; Colorectal cancer; Gastroenterology; Fluorouracil; Capecitabine; Surgery; Oncology; Randomized controlled trial; Chemotherapy; Cancer","retraction":null,"screen_n_in":null,"score":{"opus":0.1741197648038616,"gpt":0.4876139936765206,"spread":0.3134942288726591,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.007878307,0.0002802633,0.007764979,0.0001904893,0.00006217862,0.000004989469,0.0001751395,0.000174094,0.0001441318],"category_scores_gemma":[0.01227121,0.0001161914,0.001270829,0.0002928716,0.0005033391,0.00004799999,0.00006668251,0.0003722215,7.705389e-7],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0005090489,"about_ca_system_score_gemma":0.002431784,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.005765606,"about_ca_topic_score_gemma":0.04026205,"domain_scores_codex":[0.9910022,0.001265998,0.006568719,0.0002567101,0.0006391401,0.000267234],"domain_scores_gemma":[0.9614395,0.03345225,0.004109135,0.0002027279,0.0006196193,0.0001767313],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9073694,0.01735956,0.01240658,0.000009628816,0.005481162,0.0006294564,0.001687786,0.0001112308,0.00001488475,0.000006684456,0.0001951509,0.05472847],"study_design_scores_gemma":[0.8338621,0.09850086,0.06096875,0.0001048423,0.003937589,0.00002057059,0.00101317,0.0001720225,0.00007049687,0.00005984934,0.001209885,0.00007985874],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9865525,0.002762376,0.00001310308,0.004017828,0.001665405,0.004580766,0.0000603052,0.000004962434,0.0003427652],"genre_scores_gemma":[0.9905751,0.007561838,0.0004647114,0.0001713478,0.0008887902,0.0001376118,0.00000548934,0.00001460431,0.0001805301],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.0811413,"threshold_uncertainty_score":0.9960489,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W1974365898","doi":"10.1001/jama.2010.1535","title":"Association of KRAS p.G13D Mutation With Outcome in Patients With Chemotherapy-Refractory Metastatic Colorectal Cancer Treated With Cetuximab","year":2010,"lang":"en","type":"article","venue":"JAMA","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":747,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Ontario Institute for Cancer Research; Ottawa Hospital","funders":"Associazione Italiana per la Ricerca sul Cancro; Celgene; AstraZeneca; Flinders University; Bristol-Myers Squibb; Vlaamse regering; Amgen","keywords":"Cetuximab; KRAS; Medicine; Colorectal cancer; Oncology; Internal medicine; Hazard ratio; Cancer; Confidence interval","retraction":null,"screen_n_in":null,"score":{"opus":0.00824824298040603,"gpt":0.2655267310294429,"spread":0.2572784880490368,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00008084576,0.000171822,0.0004180758,0.00009913973,0.00003810682,0.00001199084,0.0000322394,0.00005731212,0.00009199301],"category_scores_gemma":[0.00003740692,0.00009769834,0.00002908097,0.0002866036,0.00005444579,0.0001230511,0.000006330945,0.0001884217,0.000001712405],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0003400083,"about_ca_system_score_gemma":0.0001087155,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001324673,"about_ca_topic_score_gemma":0.009066923,"domain_scores_codex":[0.9989995,0.00002404268,0.0002094845,0.00020199,0.0003797198,0.0001852613],"domain_scores_gemma":[0.9991974,0.00006921864,0.0002569472,0.0001027661,0.0003258541,0.00004780658],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.005932427,0.0007301603,0.9826745,0.00004329432,0.0005926254,0.00001620247,0.0008335627,0.00000711231,0.000287859,0.000002972291,0.00004845897,0.008830841],"study_design_scores_gemma":[0.02082844,0.00350889,0.9730683,0.00007499965,0.0003355868,0.000002457246,0.0001135371,0.00003464797,0.001767611,0.000002527882,0.0001436097,0.0001194115],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9979302,0.0000356554,0.00000329262,0.0005222417,0.00003665856,0.0006848421,0.00004079682,0.00002479995,0.0007215176],"genre_scores_gemma":[0.9989575,0.00001048267,0.00029744,0.0001191692,0.00002714498,0.0001379702,0.00005350347,0.00002616002,0.0003706097],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.01489602,"threshold_uncertainty_score":0.5059556,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2168579528","doi":"10.1016/s1470-2045(13)70154-2","title":"Bevacizumab plus capecitabine versus capecitabine alone in elderly patients with previously untreated metastatic colorectal cancer (AVEX): an open-label, randomised phase 3 trial","year":2013,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":654,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Ottawa Hospital","funders":"National Institutes of Health; Institute of Cancer Research; NIHR Biomedical Research Centre, Royal Marsden NHS Foundation Trust/Institute of Cancer Research; F. Hoffmann-La Roche","keywords":"Capecitabine; Medicine; Bevacizumab; Internal medicine; Irinotecan; Colorectal cancer; Hazard ratio; Clinical endpoint; Oxaliplatin; Adverse effect; Oncology; Population; Cancer; Randomized controlled trial; Chemotherapy; Surgery; Confidence interval","retraction":null,"screen_n_in":null,"score":{"opus":0.06574882485102473,"gpt":0.374869717678169,"spread":0.3091208928271442,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0004238308,0.0004476239,0.001994694,0.0001212874,0.0002149353,0.00006826624,0.0004199024,0.0001162936,0.00109658],"category_scores_gemma":[0.000185975,0.0002528836,0.00005703213,0.0004775462,0.0002883559,0.0002746817,0.0001581196,0.0003787011,0.00004089069],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001315056,"about_ca_system_score_gemma":0.0007195428,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_topic_score_codex":0.006675649,"about_ca_topic_score_gemma":0.02527192,"domain_scores_codex":[0.9971182,0.0004929546,0.0006247403,0.0005871727,0.0003625489,0.0008143731],"domain_scores_gemma":[0.9981194,0.0005410101,0.0003147205,0.0004732918,0.0003283707,0.0002231868],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9297702,0.005495191,0.00143445,0.00004483897,0.001243968,0.0001405864,0.002227538,0.0000184968,0.0003477851,0.0000239909,0.001891433,0.05736152],"study_design_scores_gemma":[0.9241968,0.05920648,0.01129671,0.00006931159,0.0009945101,0.00001691035,0.0003758174,0.0003825999,0.00009886155,0.0000384112,0.0030199,0.0003036669],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9819716,0.0008351921,0.000004619072,0.002961465,0.00057799,0.01009613,0.0001022712,0.0000722585,0.003378429],"genre_scores_gemma":[0.9919069,0.0003840311,0.00049284,0.0004779059,0.0003971311,0.005576536,0.0002802889,0.00005545378,0.0004288665],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.05705786,"threshold_uncertainty_score":0.9999923,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2123133140","doi":"10.1200/jco.2003.11.126","title":"Superiority of Oxaliplatin and Fluorouracil-Leucovorin Compared With Either Therapy Alone in Patients With Progressive Colorectal Cancer After Irinotecan and Fluorouracil-Leucovorin: Interim Results of a Phase III Trial","year":2003,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":645,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Ontario Institute for Cancer Research","funders":"National Cancer Institute; Sanofi","keywords":"Medicine; Oxaliplatin; Irinotecan; Fluorouracil; Internal medicine; Colorectal cancer; Gastroenterology; Interim analysis; Bolus (digestion); Oncology; Chemotherapy; Surgery; Cancer; Clinical trial","retraction":null,"screen_n_in":null,"score":{"opus":0.06821672524614635,"gpt":0.421301268873285,"spread":0.3530845436271386,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001053713,0.0002714481,0.002383494,0.000137822,0.00003738355,0.000009060866,0.0000739983,0.0002108161,0.00005746009],"category_scores_gemma":[0.0004865907,0.000155386,0.0001461768,0.0001983837,0.0006522878,0.0001324054,0.00004372423,0.000544913,1.338229e-7],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0001678297,"about_ca_system_score_gemma":0.0008639966,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0002878081,"about_ca_topic_score_gemma":0.001238281,"domain_scores_codex":[0.9965281,0.0004307329,0.002035191,0.0003145482,0.0004288731,0.0002624924],"domain_scores_gemma":[0.9965268,0.0007253302,0.001707419,0.0001459599,0.0006637995,0.0002307058],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"observational","study_design_scores_codex":[0.516697,0.004949277,0.4402175,0.00003134008,0.0007235322,0.0001835543,0.001220978,0.000001597593,0.00007299802,0.000002741387,0.00001744784,0.03588197],"study_design_scores_gemma":[0.3187706,0.1123901,0.5664096,0.0003029619,0.0002760507,0.00005309722,0.0003777724,0.000008446112,0.0006109278,0.000009441926,0.0006679326,0.000123068],"study_design_candidate":"observational","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9962791,0.001640682,0.000003857191,0.0003733655,0.0002590794,0.001112009,0.00005445487,0.00000447434,0.0002729291],"genre_scores_gemma":[0.9979439,0.0006840274,0.001037806,0.00008493537,0.0001383487,0.00006223228,0.00000378129,0.00001916534,0.00002583945],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.1979265,"threshold_uncertainty_score":0.6336455,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2159179344","doi":"10.1093/annonc/mdu141","title":"Final results from PRIME: randomized phase III study of panitumumab with FOLFOX4 for first-line treatment of metastatic colorectal cancer","year":2014,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":604,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Credit Valley Hospital; Mount Sinai Hospital","funders":"","keywords":"Medicine; Panitumumab; KRAS; Internal medicine; Hazard ratio; Colorectal cancer; Clinical endpoint; Randomized controlled trial; Oxaliplatin; Confidence interval; Oncology; Adverse effect; Gastroenterology; Cancer","retraction":null,"screen_n_in":null,"score":{"opus":0.1282057758737968,"gpt":0.4285832052192958,"spread":0.300377429345499,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003633903,0.0002285454,0.002333563,0.0001048388,0.00005567128,0.000001831522,0.00006535555,0.00005485798,0.00004356536],"category_scores_gemma":[0.0002835148,0.0001376307,0.0002388195,0.0001306345,0.0002524133,0.00002787587,0.00002350144,0.00004308587,3.722904e-7],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00008348451,"about_ca_system_score_gemma":0.0002803397,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.005204723,"about_ca_topic_score_gemma":0.007508767,"domain_scores_codex":[0.9982392,0.0001671035,0.0008556676,0.0003080136,0.0002101305,0.0002198834],"domain_scores_gemma":[0.9966061,0.001841361,0.0007536445,0.0002136377,0.000513322,0.00007196411],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.861491,0.01879717,0.001070982,0.00007075431,0.006666163,0.00002406975,0.008293414,0.00006825875,0.0006047694,0.00003324783,0.0002846929,0.1025955],"study_design_scores_gemma":[0.7819562,0.1851725,0.003532069,0.000098597,0.003484737,0.000004714266,0.0009435942,0.0004660705,0.02163986,0.0001542188,0.002423671,0.0001238134],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9930429,0.00122658,0.0001412222,0.001121285,0.0001005512,0.003205214,0.000506847,0.00001106682,0.0006443138],"genre_scores_gemma":[0.9971752,0.0008798633,0.0006250475,0.0000544591,0.00007490952,0.000931768,0.00008935799,0.00001669177,0.0001527459],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.1663753,"threshold_uncertainty_score":0.7868019,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2165741055","doi":"10.1093/annonc/mdp233","title":"Safety and efficacy of first-line bevacizumab with FOLFOX, XELOX, FOLFIRI and fluoropyrimidines in metastatic colorectal cancer: the BEAT study","year":2009,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":534,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"University of Toronto; Sunnybrook Health Science Centre","funders":"National Institute for Health and Care Research; Roche","keywords":"Medicine; Bevacizumab; Irinotecan; Oxaliplatin; Internal medicine; Capecitabine; FOLFOX; FOLFIRI; Colorectal cancer; Oncology; Fluorouracil; Surgery; Chemotherapy; Chemotherapy regimen; Cancer","retraction":null,"screen_n_in":null,"score":{"opus":0.05728466980328281,"gpt":0.3809595963763208,"spread":0.323674926573038,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002592434,0.0001729725,0.0008164067,0.00009498497,0.00008190419,0.00000377027,0.00005881551,0.00004177831,0.00001638874],"category_scores_gemma":[0.0001009324,0.00009702013,0.00004541014,0.000225256,0.0002514781,0.00004049234,0.00004994543,0.0001049687,1.648388e-7],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00004553675,"about_ca_system_score_gemma":0.0001155585,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0008609639,"about_ca_topic_score_gemma":0.007874603,"domain_scores_codex":[0.9989371,0.00007966645,0.0003807896,0.000239439,0.0001575381,0.0002054529],"domain_scores_gemma":[0.9990652,0.0004210878,0.0001682134,0.0001322042,0.0001548631,0.00005845737],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"observational","study_design_scores_codex":[0.03338212,0.005452477,0.4482034,0.0001483684,0.00164705,0.0002363987,0.01345062,0.00007526408,0.0003539927,0.0001467382,0.0004266736,0.4964769],"study_design_scores_gemma":[0.01094436,0.04358141,0.9403004,0.00009319728,0.0004705076,0.00005281216,0.001630575,0.00006040074,0.0009715042,0.0001140074,0.001678141,0.000102662],"study_design_candidate":"observational","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9799595,0.007384201,0.000002385036,0.01077053,0.00003262853,0.00101086,0.00002014422,0.000008570974,0.0008111059],"genre_scores_gemma":[0.9938465,0.005678392,0.0000941021,0.0002532211,0.00002673457,0.00004773676,0.000003942802,0.000008315847,0.00004100499],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.4963743,"threshold_uncertainty_score":0.4394214,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2098499757","doi":"10.1016/s1470-2045(12)70509-0","title":"Bevacizumab plus oxaliplatin-based chemotherapy as adjuvant treatment for colon cancer (AVANT): a phase 3 randomised controlled trial","year":2012,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":526,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"Genentech","keywords":"Bevacizumab; Medicine; Oxaliplatin; Capecitabine; Colorectal cancer; Clinical endpoint; Internal medicine; Bolus (digestion); Chemotherapy; Fluorouracil; Surgery; Gastroenterology; Phases of clinical research; Randomized controlled trial; Cancer","retraction":null,"screen_n_in":null,"score":{"opus":0.0801800099192156,"gpt":0.4280330432983145,"spread":0.3478530333790989,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005724936,0.0003156507,0.002027873,0.00005234278,0.0002471486,0.00001157534,0.0001048627,0.0001398992,0.0005713242],"category_scores_gemma":[0.0001673746,0.0001629429,0.0004074061,0.00007710455,0.0001460515,0.00003226633,0.00001565423,0.0001187245,0.00002036922],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001428075,"about_ca_system_score_gemma":0.0008154335,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0002554028,"about_ca_topic_score_gemma":0.0003901502,"domain_scores_codex":[0.9982659,0.0002155134,0.0004223484,0.0002643183,0.0001818896,0.0006499903],"domain_scores_gemma":[0.9978201,0.001327491,0.0002780635,0.0003180887,0.0001073486,0.0001488621],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9428982,0.002180911,0.0001455033,0.00002760546,0.001502522,0.00001388905,0.002128883,0.00001612327,0.001051028,0.00006888897,0.003870051,0.04609637],"study_design_scores_gemma":[0.8285955,0.01749676,0.0002163139,0.00002242246,0.001284634,0.0000149775,0.000150088,0.0005906598,0.001529209,0.00003741248,0.1499196,0.0001423801],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9556504,0.004255192,0.00005598793,0.01802345,0.001551476,0.01480889,0.0001053399,0.00009409279,0.005455208],"genre_scores_gemma":[0.9728013,0.0009471041,0.0002663637,0.003913471,0.003305107,0.01611023,0.00005197626,0.00003811669,0.002566319],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.1460496,"threshold_uncertainty_score":0.6644619,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2138926750","doi":"10.1093/annonc/mdf089","title":"First-line oral capecitabine therapy in metastatic colorectal cancer: a favorable safety profile compared with intravenous5-fluorouracil/leucovorin","year":2002,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":524,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Ottawa Regional Cancer Foundation","funders":"","keywords":"Capecitabine; Medicine; Internal medicine; Neutropenia; Fluorouracil; Gastroenterology; Regimen; Adverse effect; Colorectal cancer; Nausea; Febrile neutropenia; Oncology; Surgery; Cancer; Chemotherapy","retraction":null,"screen_n_in":null,"score":{"opus":0.09844456695473171,"gpt":0.3593883428312434,"spread":0.2609437758765117,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0002136499,0.0002663375,0.001141843,0.0001548223,0.00009891771,0.000006517759,0.00009996368,0.00007753185,0.001105051],"category_scores_gemma":[0.00004067087,0.0001873534,0.00009742535,0.0003935317,0.0002190109,0.00006752184,0.00003867528,0.0002098933,0.00001281336],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0002396011,"about_ca_system_score_gemma":0.0002285294,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00308702,"about_ca_topic_score_gemma":0.01700832,"domain_scores_codex":[0.9983422,0.0001015752,0.0005025347,0.0003356426,0.0002393751,0.0004786513],"domain_scores_gemma":[0.9990255,0.0001797649,0.0002114133,0.0001782925,0.0002856802,0.0001194086],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"observational","study_design_scores_codex":[0.03357046,0.01038279,0.1085507,0.0003722094,0.003050343,0.001344809,0.0115387,0.001164958,0.001492694,0.0002462873,0.007340559,0.8209454],"study_design_scores_gemma":[0.06949682,0.1657711,0.4851658,0.0007971133,0.0007188258,0.0006141078,0.003267601,0.00813991,0.0218897,0.0004343684,0.242325,0.001379549],"study_design_candidate":"design_other","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9742979,0.004661583,0.00001508172,0.007175839,0.0001041942,0.001144717,0.00009831374,0.0000372847,0.01246503],"genre_scores_gemma":[0.9904985,0.006773556,0.0008509413,0.0005445865,0.00006307262,0.0003767599,0.0000276638,0.00002619675,0.0008387368],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.8195659,"threshold_uncertainty_score":0.9998081,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2037339308","doi":"10.1200/jco.2007.11.2144","title":"Irinotecan Fluorouracil Plus Leucovorin Is Not Superior to Fluorouracil Plus Leucovorin Alone As Adjuvant Treatment for Stage III Colon Cancer: Results of CALGB 89803","year":2007,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":447,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"University of Alberta","funders":"National Cancer Institute; Pfizer","keywords":"Medicine; Irinotecan; Fluorouracil; Bolus (digestion); Regimen; Colorectal cancer; Adjuvant; Internal medicine; Oncology; Toxicity; Adjuvant therapy; Surgery; Gastroenterology; Chemotherapy; Cancer","retraction":null,"screen_n_in":null,"score":{"opus":0.178085407871939,"gpt":0.4903242408471618,"spread":0.3122388329752227,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.003326516,0.000512081,0.004320019,0.0002872334,0.0001820881,0.00001702988,0.0002960699,0.0005687972,0.0001903361],"category_scores_gemma":[0.002513339,0.0003577711,0.001198226,0.000326538,0.0003026398,0.0001355581,0.0001480245,0.0006927901,0.00001976172],"about_ca_system_candidate":true,"about_ca_system_consensus":true,"about_ca_system_score_codex":0.004396257,"about_ca_system_score_gemma":0.005637401,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.006036966,"about_ca_topic_score_gemma":0.01064105,"domain_scores_codex":[0.9929101,0.0002129483,0.004565418,0.0006344694,0.0008435695,0.0008335047],"domain_scores_gemma":[0.9917238,0.003290529,0.002195226,0.0004649732,0.001329858,0.0009956198],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.2781291,0.003778917,0.006173752,0.0001376499,0.002867274,0.002409483,0.004527862,0.0002116985,0.002757485,0.00007283653,0.007141927,0.691792],"study_design_scores_gemma":[0.1116935,0.192091,0.08282132,0.0004303801,0.002392172,0.0003905219,0.002409512,0.0001575817,0.02683151,0.00005305945,0.5801757,0.0005537558],"study_design_candidate":"design_other","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9746517,0.002501422,0.0002270223,0.01598603,0.002279253,0.001631386,0.0003744076,0.00002673537,0.002322042],"genre_scores_gemma":[0.9792805,0.004079297,0.003190614,0.002654705,0.001784174,0.0001120882,0.00001519549,0.00005301501,0.008830367],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.6912382,"threshold_uncertainty_score":0.9999997,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2084330540","doi":"10.1038/sj.bjc.6601676","title":"Oral capecitabine vs intravenous 5-fluorouracil and leucovorin: integrated efficacy data and novel analyses from two large, randomised, phase III trials","year":2004,"lang":"en","type":"article","venue":"British Journal of Cancer","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":398,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Ottawa Regional Cancer Foundation","funders":"","keywords":"Capecitabine; Medicine; Internal medicine; Hazard ratio; Fluorouracil; Regimen; Confidence interval; Gastroenterology; Population; Proportional hazards model; Colorectal cancer; Oncology; Surgery; Chemotherapy; Cancer","retraction":null,"screen_n_in":null,"score":{"opus":0.1004104825505594,"gpt":0.4197499322979251,"spread":0.3193394497473658,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007506731,0.0002165988,0.001461687,0.0000924992,0.0001537573,0.0001218333,0.0001272964,0.00005823388,0.0002477088],"category_scores_gemma":[0.0006953559,0.0001701881,0.0001370593,0.0001704989,0.0001190388,0.0002517171,0.00009435774,0.0002968302,4.981794e-7],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.000185917,"about_ca_system_score_gemma":0.0003959446,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.009698042,"about_ca_topic_score_gemma":0.007844936,"domain_scores_codex":[0.9981767,0.00007976372,0.0008559845,0.0003011774,0.0003317113,0.000254643],"domain_scores_gemma":[0.9985673,0.0002420102,0.0004584786,0.0001742399,0.0003204479,0.0002374948],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.06280386,0.001612749,0.001850243,0.00004264151,0.005911595,0.002266887,0.0008056047,0.00004799058,0.007300331,0.00001071946,0.001603628,0.9157438],"study_design_scores_gemma":[0.8974772,0.002725196,0.04477843,0.002136899,0.007309041,0.004070607,0.001122653,0.0001999845,0.003018076,0.0001849846,0.03647838,0.0004985289],"study_design_candidate":"randomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.8904876,0.1053335,0.001553436,0.0007246131,0.0002899813,0.0004141874,0.001101929,0.00001241575,0.00008239916],"genre_scores_gemma":[0.96434,0.0329404,0.001471982,0.0002555299,0.0007710001,0.00001190092,0.00009726555,0.0000221341,0.00008980287],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.9152452,"threshold_uncertainty_score":0.9968964,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W1870066362","doi":"10.1200/jco.2004.03.104","title":"Modulation of Fluorouracil by Leucovorin in Patients With Advanced Colorectal Cancer: An Updated Meta-Analysis","year":2004,"lang":"en","type":"review","venue":"Journal of Clinical Oncology","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":387,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Hôpital Saint-Luc","funders":"","keywords":"Medicine; Folinic acid; Fluorouracil; Internal medicine; Colorectal cancer; Meta-analysis; Randomized controlled trial; Odds ratio; Oncology; Hazard ratio; Gastroenterology; Confidence interval; Cancer","retraction":null,"screen_n_in":null,"score":{"opus":0.1748375784886754,"gpt":0.4978436670426455,"spread":0.3230060885539702,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001212087,0.0004021475,0.01351136,0.0004262701,0.00003001037,0.000005717781,0.0001851957,0.0005515182,0.0002643294],"category_scores_gemma":[0.000319963,0.0002181424,0.003016436,0.0007449639,0.0001670367,0.0001574497,0.0000441453,0.0009528698,0.000001273844],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001020942,"about_ca_system_score_gemma":0.002778344,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0001979514,"about_ca_topic_score_gemma":0.0009183317,"domain_scores_codex":[0.9939404,0.0006526402,0.004163913,0.0003880709,0.0006083275,0.0002467173],"domain_scores_gemma":[0.992458,0.0005959907,0.005601622,0.0002274466,0.0008647904,0.0002521882],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"meta_analysis","study_design_scores_codex":[0.004582199,0.00374088,0.0137605,0.0005286142,0.1695047,0.0000861505,0.00005301481,0.0002104907,2.035295e-7,0.000002702014,0.00009928028,0.8074313],"study_design_scores_gemma":[0.01234068,0.04249369,0.09654461,0.0007871721,0.6473466,0.00001821914,0.00002860349,0.00001348818,0.000001418965,0.00001785415,0.2000788,0.0003289037],"study_design_candidate":"meta_analysis","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.06693985,0.9314294,0.00001233009,0.0001732508,0.0002832873,0.0008413238,0.0001567966,0.000006294638,0.0001574677],"genre_scores_gemma":[0.07876161,0.9197164,0.0009352174,0.0000648815,0.0001142754,0.0000562872,0.0002422147,0.00003244324,0.00007664239],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.8071024,"threshold_uncertainty_score":0.9236094,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2142019712","doi":"10.1158/1078-0432.ccr-07-1061","title":"Bendamustine (Treanda) Displays a Distinct Pattern of Cytotoxicity and Unique Mechanistic Features Compared with Other Alkylating Agents","year":2008,"lang":"en","type":"article","venue":"Clinical Cancer Research","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":366,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Université Laval","funders":"National Cancer Institute; University of California, San Diego; National Institutes of Health","keywords":"Bendamustine; DNA damage; DNA repair; Biology; Nitrogen mustard; Mitotic catastrophe; Mechanism of action; Chlorambucil; Cancer research; DNA; Pharmacology; Chemotherapy; In vitro; Genetics; Leukemia; Chronic lymphocytic leukemia; Cyclophosphamide","retraction":null,"screen_n_in":null,"score":{"opus":0.2350859728693352,"gpt":0.4859579457032853,"spread":0.2508719728339501,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000557129,0.0001727678,0.0006168088,0.00007890179,0.000280331,0.00001131788,0.00009469981,0.00008479538,0.0002387557],"category_scores_gemma":[0.0003268997,0.0001106309,0.00007974534,0.000264284,0.0007664407,0.00003018507,0.0001556961,0.0005032031,0.000002340816],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0001132606,"about_ca_system_score_gemma":0.0002301627,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.002835558,"about_ca_topic_score_gemma":0.003087785,"domain_scores_codex":[0.9980127,0.0001861837,0.0003965488,0.0004273221,0.0006116266,0.0003655838],"domain_scores_gemma":[0.998357,0.0007130438,0.0001083867,0.0002530903,0.0003392708,0.0002292069],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.003335789,0.0005279786,0.9843547,0.000251577,0.0003717832,0.0001879806,0.0007177399,0.000003399374,0.0003632689,0.00003556251,0.001388287,0.008461879],"study_design_scores_gemma":[0.003599187,0.002379883,0.9912297,0.0004582189,0.00009697139,0.00004528318,0.0001915362,0.0002563483,0.000810837,0.00005156115,0.0007483475,0.0001320983],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9952978,0.0008048369,0.0001432868,0.0006162836,0.00004206966,0.0006400478,0.0001236173,0.00002411155,0.002307929],"genre_scores_gemma":[0.9979407,0.0005789473,0.0001895212,0.0001330211,0.0001661171,0.0001239129,0.00001339063,0.00002761218,0.0008267686],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.00832978,"threshold_uncertainty_score":0.4511398,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W1799482054","doi":"10.1016/j.ejca.2015.03.015","title":"Location of colon cancer (right-sided versus left-sided) as a prognostic factor and a predictor of benefit from cetuximab in NCIC CO.17","year":2015,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":337,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"CancerCare Manitoba; University Health Network; University of Toronto; Ottawa Hospital; Princess Margaret Cancer Centre; University of Ottawa","funders":"","keywords":"Cetuximab; Medicine; KRAS; Internal medicine; Colorectal cancer; Oncology; Hazard ratio; Proportional hazards model; Epidermal growth factor receptor; Refractory (planetary science); Splenic flexure; Cancer; Gastroenterology; Confidence interval; Colonoscopy; Biology","retraction":null,"screen_n_in":null,"score":{"opus":0.04018596104969974,"gpt":0.3208746865091295,"spread":0.2806887254594298,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002025648,0.000159876,0.0005381946,0.0001347158,0.00002320318,0.000009475396,0.00008585541,0.00002868848,0.0001601117],"category_scores_gemma":[0.0003495577,0.0001168943,0.00006299964,0.0001672714,0.0001086726,0.0001016292,0.00003482719,0.000161292,0.000001917378],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0003295217,"about_ca_system_score_gemma":0.0005571092,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0009381041,"about_ca_topic_score_gemma":0.001538511,"domain_scores_codex":[0.9986045,0.00008731088,0.0005655431,0.0001596249,0.0004252171,0.0001577606],"domain_scores_gemma":[0.9982871,0.0001421082,0.0005404392,0.0001173752,0.000751297,0.0001616779],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.02975624,0.0008111629,0.8912815,0.0003844606,0.002120956,0.0006064733,0.01837196,0.0003545055,0.006963641,0.00002678665,0.004589533,0.0447328],"study_design_scores_gemma":[0.01772936,0.004977703,0.9645892,0.002569127,0.0005740181,0.00002395908,0.0007037734,0.00006579794,0.005689068,0.00004919089,0.00287898,0.0001498452],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9675257,0.02953825,0.000008683612,0.0004418391,0.0003992159,0.0002748029,0.00007278815,0.000006205964,0.001732562],"genre_scores_gemma":[0.997896,0.001401184,0.0001125968,0.00005633356,0.0002452899,0.000007577117,0.000004390321,0.0000236839,0.0002529507],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.07330769,"threshold_uncertainty_score":0.4766811,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2126251787","doi":"10.1200/jco.2011.38.7571","title":"Progression-Free Survival: Meaningful or Simply Measurable?","year":2012,"lang":"en","type":"editorial","venue":"Journal of Clinical Oncology","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":320,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Queen's University","funders":"","keywords":"Medicine; Progression-free survival; Oncology; Randomized controlled trial; Internal medicine; Clinical endpoint; Standard of care; Overall survival; Tumor progression; Intensive care medicine; Cancer","retraction":null,"screen_n_in":null,"score":{"opus":0.1833612787865125,"gpt":0.5217916929448325,"spread":0.33843041415832,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaresearch","research_integrity"],"consensus_categories":["research_integrity"],"category_scores_codex":[0.008012476,0.0004625916,0.005141565,0.0001936265,0.0001117368,0.00002200895,0.0005298231,0.002290798,0.0005888345],"category_scores_gemma":[0.06972166,0.0002446937,0.001288614,0.0002140482,0.0003470347,0.0001362537,0.0003030274,0.003919831,0.00003785829],"about_ca_system_candidate":true,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0007244423,"about_ca_system_score_gemma":0.008939453,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00004777374,"about_ca_topic_score_gemma":0.000442916,"domain_scores_codex":[0.9920408,0.0007679288,0.003913119,0.0003718089,0.002330082,0.000576303],"domain_scores_gemma":[0.974564,0.01638949,0.004949574,0.0005520552,0.002672383,0.0008725655],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","study_design_scores_codex":[0.01991699,0.002052569,0.004031083,0.0001255817,0.002343416,0.001349045,0.00007977214,1.76203e-7,0.000001374091,0.000008017683,0.8103203,0.1597717],"study_design_scores_gemma":[0.01260395,0.03180341,0.006858095,0.0006212528,0.002937802,0.0001497643,0.0001064581,9.075651e-7,0.000003515525,0.0001829869,0.9445081,0.0002236908],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","genre_codex":"editorial","genre_gemma":"editorial","genre_scores_codex":[0.001109287,0.005711638,0.00001419699,0.005686074,0.9625406,0.0004262368,0.00004849059,0.00003045316,0.02443307],"genre_scores_gemma":[0.003307388,0.01008271,0.002420382,0.0004767553,0.9808048,0.00002401888,0.000022186,0.00008396426,0.002777781],"genre_candidate":"editorial","genre_consensus":"editorial","teacher_disagreement_score":0.159548,"threshold_uncertainty_score":0.9990044,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2770347143","doi":"10.1158/1078-0432.ccr-17-2484","title":"Classifying Colorectal Cancer by Tumor Location Rather than Sidedness Highlights a Continuum in Mutation Profiles and Consensus Molecular Subtypes","year":2017,"lang":"en","type":"article","venue":"Clinical Cancer Research","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":318,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false},"ca_institutions":"","funders":"National Center for Advancing Translational Sciences; National Cancer Institute; Royal College of Physicians and Surgeons of Canada; Conquer Cancer Foundation","keywords":"KRAS; Splenic flexure; Colorectal cancer; Medicine; Mutation; GNAS complex locus; Internal medicine; Cancer; Rectum; Oncology; Cancer research; Gastroenterology; Biology; Genetics; Gene; Colonoscopy","retraction":null,"screen_n_in":null,"score":{"opus":0.1301473757666578,"gpt":0.4891342404451145,"spread":0.3589868646784567,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009665174,0.0001698565,0.0004931192,0.00009948245,0.0004022096,0.0001083311,0.0001346761,0.0001243343,0.00006411365],"category_scores_gemma":[0.001024893,0.0001297007,0.00006417582,0.0001701022,0.0009407917,0.00007572746,0.0001363589,0.0004601984,0.00000772476],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0003146465,"about_ca_system_score_gemma":0.0005970256,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.006442771,"about_ca_topic_score_gemma":0.01337367,"domain_scores_codex":[0.9978769,0.0002609548,0.0004275259,0.0005582456,0.0004516729,0.0004247253],"domain_scores_gemma":[0.9983656,0.0004634035,0.0001677555,0.0002739954,0.00055381,0.0001754118],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.004812913,0.0004443045,0.9503385,0.0002641682,0.0002804542,0.0005011125,0.0007078078,0.000002007584,0.01179423,0.0002059142,0.00498125,0.02566734],"study_design_scores_gemma":[0.005020266,0.0009329814,0.9679121,0.0005421491,0.00007819728,0.00001116482,0.0004744185,0.0002803003,0.02137338,0.0003053443,0.002870423,0.0001992491],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9801762,0.007750572,0.000002950209,0.009600994,0.0002829297,0.001080075,0.00003618873,0.00002375033,0.001046385],"genre_scores_gemma":[0.9962779,0.001514072,0.00003745129,0.0001226541,0.0002027842,0.0008488026,0.00001120027,0.00002765416,0.000957431],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.02546809,"threshold_uncertainty_score":0.9739586,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2152511454","doi":"10.1093/annonc/mdg500","title":"Oral capecitabine as an alternative to i.v. 5-fluorouracil-based adjuvant therapy for colon cancer: safety results of a randomized, phase III trial","year":2003,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":275,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Ottawa Regional Cancer Foundation","funders":"F. Hoffmann-La Roche","keywords":"Capecitabine; Medicine; Internal medicine; Neutropenia; Fluorouracil; Stomatitis; Nausea; Regimen; Gastroenterology; Colorectal cancer; Adjuvant therapy; Surgery; Cancer; Oncology; Chemotherapy","retraction":null,"screen_n_in":null,"score":{"opus":0.09975016200087691,"gpt":0.454884961949826,"spread":0.3551347999489491,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001241725,0.0002076718,0.001892618,0.0001347159,0.00006880327,0.000003145002,0.00008631933,0.0001022575,0.0001317748],"category_scores_gemma":[0.0009958595,0.0001458256,0.0003389307,0.0001706924,0.0001926645,0.00004453821,0.00001409211,0.00008045639,0.000001196234],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0001243239,"about_ca_system_score_gemma":0.0007442543,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.002179899,"about_ca_topic_score_gemma":0.001105046,"domain_scores_codex":[0.9979749,0.0003420786,0.0008385259,0.0003278825,0.0002222031,0.0002943545],"domain_scores_gemma":[0.9975143,0.000869501,0.0004767744,0.0002140817,0.0007704361,0.0001548984],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.8516691,0.002950539,0.00001874008,0.00001776364,0.0008500207,0.00002024106,0.001525482,0.00004488856,0.0008533488,0.0003286937,0.00197738,0.1397438],"study_design_scores_gemma":[0.8168628,0.07970516,0.00005476948,0.00004698101,0.0002310617,0.00000372314,0.0002301333,0.0001014834,0.03211195,0.0002968517,0.07024076,0.0001143571],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9783753,0.001942441,0.0001730632,0.00780048,0.0004832955,0.005361925,0.0004942551,0.00001648331,0.00535279],"genre_scores_gemma":[0.9935693,0.00202727,0.0008585869,0.001788856,0.0001583512,0.001126282,0.00006763219,0.00001791983,0.0003858616],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.1396295,"threshold_uncertainty_score":0.5946595,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2158475201","doi":"10.1093/annonc/mdm492","title":"EGFR FISH assay predicts for response to cetuximab in chemotherapy refractory colorectal cancer patients","year":2007,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":268,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"University Hospital Foundation","funders":"Cancer Center, University of Colorado; Università degli Studi di Napoli Federico II","keywords":"Cetuximab; Medicine; Colorectal cancer; Internal medicine; Oncology; Epidermal growth factor receptor; Fluorescence in situ hybridization; Lung cancer; KRAS; Confidence interval; Cancer; Chemotherapy; Gene; Biology","retraction":null,"screen_n_in":null,"score":{"opus":0.04960752627918864,"gpt":0.403707058447591,"spread":0.3540995321684024,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008399459,0.0001444135,0.0005267847,0.0002006607,0.00004015566,0.00000234877,0.00007058055,0.0001490567,0.00007528132],"category_scores_gemma":[0.0004187256,0.0001106076,0.0000990776,0.0002174837,0.00007419479,0.00003742854,0.00003332687,0.0001025363,0.000002410746],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0003718251,"about_ca_system_score_gemma":0.0002883918,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0002705935,"about_ca_topic_score_gemma":0.002266087,"domain_scores_codex":[0.9987497,0.00006665437,0.0003697075,0.0002553893,0.0001742212,0.0003843468],"domain_scores_gemma":[0.9986531,0.0006189916,0.0001302233,0.0001071572,0.0003618094,0.0001286995],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"observational","study_design_scores_codex":[0.1401529,0.004341243,0.2441864,0.00007943573,0.0003884334,0.00006093105,0.005114248,0.000003593569,0.008119363,0.00001090305,0.04013401,0.5574085],"study_design_scores_gemma":[0.006560963,0.01925937,0.7159299,0.0000533871,0.00002512375,0.000001756147,0.0001527243,0.000003743709,0.01375516,0.00002166227,0.2441484,0.00008784496],"study_design_candidate":"observational","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9831051,0.000221913,0.00001308519,0.01143066,0.0002624968,0.001045422,0.00009373659,0.00001860847,0.003808946],"genre_scores_gemma":[0.9930621,0.0002945121,0.0002880084,0.005397374,0.0001183989,0.0002243844,0.00001766097,0.00002033496,0.0005772433],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.5573207,"threshold_uncertainty_score":0.4510447,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2121313610","doi":"10.1200/jco.2007.15.2090","title":"Potential Regional Differences for the Tolerability Profiles of Fluoropyrimidines","year":2008,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":253,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Institute of Cancer Research","funders":"National Institute for Health and Care Research","keywords":"Tolerability; Medicine; Oncology; Pharmacology; Internal medicine; Adverse effect","retraction":null,"screen_n_in":null,"score":{"opus":0.2520781100918678,"gpt":0.4719691598207691,"spread":0.2198910497289013,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008586531,0.00008060227,0.001034644,0.00002840137,0.00009321902,0.000001548741,0.0001027394,0.000114363,0.00007091071],"category_scores_gemma":[0.002085312,0.00003619338,0.0005705791,0.00004981294,0.0005741221,0.00003236922,0.00002870675,0.0002331138,5.840757e-7],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00004476888,"about_ca_system_score_gemma":0.0008363593,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00002431306,"about_ca_topic_score_gemma":0.00002091102,"domain_scores_codex":[0.9981813,0.0001083064,0.001261959,0.000100119,0.0002384742,0.0001098725],"domain_scores_gemma":[0.9953505,0.002666566,0.001183568,0.0000988881,0.0006156732,0.00008483696],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.02224225,0.003457334,0.7815592,0.00007479658,0.001631071,0.000156064,0.0004132859,0.00000985421,0.0002430191,0.0002499066,0.01932838,0.1706348],"study_design_scores_gemma":[0.003482041,0.01394454,0.9682643,0.0000270106,0.000403047,0.0003251119,0.0001879815,0.00007751326,0.0001042897,0.0004872667,0.01266103,0.00003587005],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9779587,0.001916635,0.0001498645,0.01838265,0.000859711,0.0002582881,0.000005086978,0.000003100043,0.0004659929],"genre_scores_gemma":[0.9942507,0.002310321,0.001623366,0.0004602634,0.001129055,0.00001227202,6.862642e-7,0.000004256678,0.0002090965],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.1867051,"threshold_uncertainty_score":0.2496464,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W1844854109","doi":"10.1002/cncr.27935","title":"Association between adherence to National Comprehensive Cancer Network treatment guidelines and improved survival in patients with colon cancer","year":2012,"lang":"en","type":"article","venue":"Cancer","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":245,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Western University","funders":"National Cancer Institute","keywords":"Medicine; Medicaid; Cancer; Colorectal cancer; Internal medicine; Cohort; Relative survival; Population; Stage (stratigraphy); Multivariate analysis; Disease; Oncology; Cohort study; Cancer registry; Health care; Environmental health","retraction":null,"screen_n_in":null,"score":{"opus":0.07394323950985555,"gpt":0.3663922648586683,"spread":0.2924490253488128,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00007468068,0.0002003923,0.0004169507,0.00004675475,0.00009004748,0.00001239907,0.00002977512,0.00006616862,0.0001117658],"category_scores_gemma":[0.0000305415,0.000141503,0.00003216488,0.0002312314,0.00002479479,0.00008667288,0.00003227347,0.00007106685,0.000002476542],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.002601897,"about_ca_system_score_gemma":0.0002467813,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.007196943,"about_ca_topic_score_gemma":0.01291738,"domain_scores_codex":[0.9988053,0.00002768709,0.000229789,0.0002494307,0.0003093203,0.0003784825],"domain_scores_gemma":[0.9989205,0.00007736784,0.0001273837,0.00007252147,0.0006550261,0.0001472168],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.0005765071,0.00008753344,0.9678448,0.00001837729,0.0005549889,3.45782e-7,0.0004523517,0.0001244667,0.00002399943,0.000003893431,0.002942489,0.02737025],"study_design_scores_gemma":[0.003646437,0.0007825849,0.9760621,0.0001639491,0.0002577355,8.725274e-8,0.00004903348,0.00002390256,0.00006345027,0.000004827519,0.01879085,0.0001550518],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9897891,0.006639424,0.000003067987,0.001634209,0.0005126575,0.0008872565,0.0002727821,0.00001947047,0.0002420911],"genre_scores_gemma":[0.9942913,0.001410054,0.0001616353,0.0006921654,0.001055833,0.001201952,0.00004091073,0.00002010773,0.001126064],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.02721519,"threshold_uncertainty_score":0.9994142,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W4384520841","doi":"10.1200/jco.22.02760","title":"Bevacizumab in Combination With Oxaliplatin-Based Chemotherapy As First-Line Therapy in Metastatic Colorectal Cancer: A Randomized Phase III Study","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":243,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"CancerCare Manitoba","funders":"","keywords":"Bevacizumab; Medicine; Oxaliplatin; FOLFOX; Folinic acid; Internal medicine; Colorectal cancer; Oncology; Clinical endpoint; Chemotherapy; Placebo; Capecitabine; Hazard ratio; Progression-free survival; Surgery; Randomized controlled trial; Cancer; Confidence interval; Pathology","retraction":null,"screen_n_in":null,"score":{"opus":0.1009913211866394,"gpt":0.4850312222814466,"spread":0.3840399010948072,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00443902,0.000211782,0.0030807,0.0004081042,0.00004952099,0.000009192484,0.0001018907,0.000119317,0.0001613005],"category_scores_gemma":[0.001302371,0.0001247239,0.0003316078,0.0007289452,0.0002055023,0.0000683035,0.00001715447,0.000596211,0.000003865957],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0004092772,"about_ca_system_score_gemma":0.001616066,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0006169221,"about_ca_topic_score_gemma":0.005328243,"domain_scores_codex":[0.996039,0.0007741612,0.002227839,0.0002422957,0.0004602181,0.0002565028],"domain_scores_gemma":[0.9934811,0.004748355,0.001207866,0.0001065966,0.0003136087,0.0001424656],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.7555528,0.01696337,0.0880008,0.00001726229,0.001379568,0.001921171,0.001895388,0.0003839817,0.00002475509,0.000009848652,0.0001349691,0.1337161],"study_design_scores_gemma":[0.7423705,0.07871794,0.1744687,0.0001217803,0.000316125,0.00003011886,0.000700966,0.002278275,0.00005064993,0.0001950785,0.0006481174,0.0001017434],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9851435,0.0005250965,0.00001393943,0.01159435,0.0003648781,0.002073331,0.000003589123,0.0000173378,0.0002640078],"genre_scores_gemma":[0.9952333,0.003136981,0.0001993278,0.0009149828,0.0001362908,0.0002664523,0.000006104988,0.00002204932,0.00008448571],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.1336143,"threshold_uncertainty_score":0.5086092,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2120713475","doi":"10.1200/jco.2006.08.6652","title":"Neurotoxicity From Oxaliplatin Combined With Weekly Bolus Fluorouracil and Leucovorin As Surgical Adjuvant Chemotherapy for Stage II and III Colon Cancer: NSABP C-07","year":2007,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":240,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false},"ca_institutions":"","funders":"National Cancer Institute; National Institutes of Health; Michael Smith Health Research BC; Ministerul Cercetării, Inovării şi Digitalizării; U.S. Department of Health and Human Services","keywords":"Oxaliplatin; Medicine; Neurotoxicity; Bolus (digestion); Adverse effect; Chemotherapy; Gastroenterology; Internal medicine; Surgery; Fluorouracil; Colorectal cancer; Toxicity; Anesthesia; Cancer","retraction":null,"screen_n_in":null,"score":{"opus":0.07383472491052075,"gpt":0.4402460097146234,"spread":0.3664112848041026,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001492681,0.0002127639,0.001817494,0.00005843083,0.00015999,0.00001205665,0.00007115192,0.000263631,0.0001299794],"category_scores_gemma":[0.0004104304,0.0001331948,0.000192817,0.00007812229,0.0003179404,0.00007645,0.00006230031,0.0005604086,7.041653e-7],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0001753523,"about_ca_system_score_gemma":0.0006595433,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0004970586,"about_ca_topic_score_gemma":0.001436553,"domain_scores_codex":[0.9976904,0.0001120189,0.00131469,0.0002901,0.000294734,0.000298007],"domain_scores_gemma":[0.9954452,0.002781022,0.0009525439,0.0001083012,0.0002982284,0.0004146842],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"observational","study_design_scores_codex":[0.2524867,0.002662817,0.2735394,0.00005812224,0.001662615,0.00236684,0.0007767181,0.000004037203,0.0004956779,0.0001926331,0.002478799,0.4632756],"study_design_scores_gemma":[0.06648009,0.09962529,0.6591524,0.0001239305,0.0005971491,0.0003410544,0.0004049038,0.00009584963,0.0005664319,0.0002098481,0.1722131,0.0001900305],"study_design_candidate":"observational","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.984424,0.001962587,0.00006432598,0.01147011,0.0004526832,0.0006663201,0.00002834351,0.00001214489,0.0009194728],"genre_scores_gemma":[0.9909673,0.003847569,0.001355803,0.002001505,0.0007665093,0.00002095937,0.000003152435,0.00002102401,0.001016168],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.4630856,"threshold_uncertainty_score":0.5431527,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W4200445204","doi":"10.3390/curroncol28060447","title":"Pathological Features and Prognostication in Colorectal Cancer","year":2021,"lang":"en","type":"review","venue":"Current Oncology","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":239,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":false,"ca_fund":false,"ca_venue":true,"about_ca":false},"ca_institutions":"","funders":"","keywords":"Medicine; Perineural invasion; Colorectal cancer; KRAS; Pathological; Tumor budding; Lymph node; Oncology; Pathological staging; Stage (stratigraphy); Cancer; Adjuvant therapy; Disease; Microsatellite instability; Internal medicine; Pathology; Metastasis; Lymph node metastasis","retraction":null,"screen_n_in":null,"score":{"opus":0.2063818137940601,"gpt":0.503537325562874,"spread":0.2971555117688139,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00009964652,0.0002737573,0.001816644,0.0001181896,0.00004279696,0.00001040548,0.00004667406,0.0003023339,0.0000716865],"category_scores_gemma":[0.000207253,0.0001806298,0.0001639888,0.0002334143,0.0001410597,0.00001492225,0.0001224054,0.0005064841,0.000004821291],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0006258116,"about_ca_system_score_gemma":0.0006203869,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00001467843,"about_ca_topic_score_gemma":0.0002301182,"domain_scores_codex":[0.998693,0.0001663955,0.0003329475,0.0004679812,0.0001029832,0.0002366554],"domain_scores_gemma":[0.9993684,0.0002493286,0.000137278,0.00008965214,0.00007388433,0.00008146658],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.00003352254,0.0004543489,0.004661119,0.003278737,0.000102424,0.00021903,0.0001328733,8.213134e-9,2.565882e-7,0.00007795465,0.001159723,0.98988],"study_design_scores_gemma":[0.0006274462,0.000602202,0.01843434,0.006135986,0.001092459,0.0004238338,0.00003908246,6.691509e-7,5.008743e-7,0.00001149687,0.9724801,0.0001518981],"study_design_candidate":"design_other","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.00164122,0.9951925,5.349413e-7,0.0002393975,0.000739939,0.001170157,0.00004269852,0.00002372682,0.0009498232],"genre_scores_gemma":[0.0003720479,0.9972964,0.00005128578,0.00002277011,0.0002603379,0.001702297,0.0002046318,0.00001619702,0.00007403367],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.9897281,"threshold_uncertainty_score":0.7365867,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2161664263","doi":"10.1200/jco.2006.08.1935","title":"Surrogate End Points for Median Overall Survival in Metastatic Colorectal Cancer: Literature-Based Analysis From 39 Randomized Controlled Trials of First-Line Chemotherapy","year":2007,"lang":"en","type":"review","venue":"Journal of Clinical Oncology","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":238,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"","keywords":"Medicine; Surrogate endpoint; Internal medicine; Hazard ratio; Colorectal cancer; Oncology; Randomized controlled trial; Progression-free survival; Proportional hazards model; Clinical endpoint; Population; Chemotherapy; Cancer; Confidence interval; Surgery","retraction":null,"screen_n_in":null,"score":{"opus":0.2130243668631893,"gpt":0.5334961922847858,"spread":0.3204718254215966,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaresearch","metaepi_narrow","metaepi_broad"],"consensus_categories":["metaresearch","metaepi_broad"],"category_scores_codex":[0.04339261,0.0007128843,0.06840818,0.001315036,0.00004163154,0.00002136805,0.0002786199,0.0009242506,0.0005458934],"category_scores_gemma":[0.03810213,0.0003657292,0.01960921,0.0008503791,0.0003969653,0.00005693282,0.00003285708,0.001232641,8.19644e-7],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0006852209,"about_ca_system_score_gemma":0.004302415,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0004312498,"about_ca_topic_score_gemma":0.004882596,"domain_scores_codex":[0.9760242,0.006023676,0.01624569,0.0004982756,0.0007736031,0.0004345512],"domain_scores_gemma":[0.8487431,0.1337014,0.01588521,0.0002278042,0.001091866,0.0003506327],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.5069779,0.001901927,0.0007924853,0.001241256,0.07391882,0.0003253979,0.0001083383,0.00001283071,2.978029e-7,0.000008617473,0.000107749,0.4146044],"study_design_scores_gemma":[0.6976409,0.00705968,0.0006638183,0.006396654,0.1235785,0.0000118152,0.00001802719,0.0002548964,0.000003513391,0.0002910766,0.1638148,0.0002662864],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.006499632,0.981919,0.0002974667,0.002561974,0.002375025,0.005367786,0.0008252991,0.000007251541,0.0001465594],"genre_scores_gemma":[0.004460642,0.9898608,0.00287081,0.0004273927,0.001561746,0.0004308372,0.0002584256,0.00005096326,0.00007837392],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.4143381,"threshold_uncertainty_score":0.9998795,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2598954950","doi":"10.1158/2159-8290.cd-16-0795","title":"A Phase Ib Dose-Escalation Study of Encorafenib and Cetuximab with or without Alpelisib in Metastatic <i>BRAF</i> -Mutant Colorectal Cancer","year":2017,"lang":"en","type":"article","venue":"Cancer Discovery","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":230,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Princess Margaret Cancer Centre","funders":"National Cancer Institute; Seventh Framework Programme; Deutschen Konsortium für Translationale Krebsforschung","keywords":"Cetuximab; Medicine; Colorectal cancer; Tolerability; Oncology; Internal medicine; Concomitant; Cancer; Population; Pharmacology; Adverse effect","retraction":null,"screen_n_in":null,"score":{"opus":0.04112415896288415,"gpt":0.3710117573194283,"spread":0.3298875983565441,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00009970178,0.000265153,0.0007958057,0.00009761125,0.0001864795,0.00007939091,0.00009978341,0.0000348672,0.00004774456],"category_scores_gemma":[0.00003839607,0.0001618063,0.0000467859,0.0001526811,0.0002298298,0.0004569719,0.00008642351,0.0001336063,4.841176e-7],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0002702761,"about_ca_system_score_gemma":0.0004382173,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_topic_score_codex":0.008912066,"about_ca_topic_score_gemma":0.0599536,"domain_scores_codex":[0.9986125,0.00003680564,0.0003281555,0.0004341177,0.0003235432,0.0002648428],"domain_scores_gemma":[0.9991553,0.00004498741,0.0003008569,0.0003125038,0.00009697121,0.0000893757],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.02343177,0.00482821,0.9215629,0.0002885712,0.001055434,0.0003002273,0.009085322,0.00005140711,0.0035766,0.00001115934,0.000083102,0.0357253],"study_design_scores_gemma":[0.07190936,0.01576112,0.8944662,0.001007642,0.001650003,0.00004241306,0.008232155,0.0006596145,0.005633645,0.00002621269,0.0001677336,0.00044392],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9955402,0.001815877,0.00001411925,0.0002531307,0.000198815,0.00156089,0.0001403051,0.00001616939,0.0004604722],"genre_scores_gemma":[0.9977182,0.0009759439,0.00004461938,0.00007102053,0.00008123739,0.0007343558,0.000007330464,0.00002949066,0.0003377775],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.05104153,"threshold_uncertainty_score":0.9976877,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2108585052","doi":"10.1200/jco.2006.06.1440","title":"Phase III Trial Comparing 4-Day Chronomodulated Therapy Versus 2-Day Conventional Delivery of Fluorouracil, Leucovorin, and Oxaliplatin As First-Line Chemotherapy of Metastatic Colorectal Cancer: The European Organisation for Research and Treatment of Cancer Chronotherapy Group","year":2006,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":227,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Occupational Cancer Research Centre","funders":"","keywords":"Oxaliplatin; Medicine; Fluorouracil; Colorectal cancer; Internal medicine; Oncology; Chemotherapy; Phases of clinical research; Cancer","retraction":null,"screen_n_in":null,"score":{"opus":0.2516237123749373,"gpt":0.5059338816823887,"spread":0.2543101693074514,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002511861,0.000163682,0.001392841,0.0001038121,0.0001090786,0.000006899601,0.00007734802,0.0000853267,0.0001069034],"category_scores_gemma":[0.0001307212,0.00009764225,0.0002571015,0.0001152128,0.0005932489,0.00005913612,0.00002058355,0.0001736819,1.650403e-7],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0003255648,"about_ca_system_score_gemma":0.0006825096,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001860218,"about_ca_topic_score_gemma":0.002015055,"domain_scores_codex":[0.9971554,0.0005260746,0.001638445,0.0001942487,0.0003086606,0.0001771262],"domain_scores_gemma":[0.9945542,0.003246876,0.001466155,0.00009606364,0.0005553843,0.00008136354],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.4183602,0.008713089,0.01958424,0.00005506298,0.004081517,0.00001716658,0.001121304,0.00008892828,0.006994679,0.0001211376,0.0001903655,0.5406723],"study_design_scores_gemma":[0.6070731,0.202381,0.1677423,0.0001403295,0.00082755,0.00001571661,0.0003807273,0.0009335744,0.01013663,0.0003029092,0.009931711,0.0001344671],"study_design_candidate":"randomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9891604,0.007608681,0.00007512115,0.001382112,0.0004581997,0.001131364,0.00003535559,0.000003470824,0.0001452776],"genre_scores_gemma":[0.9759666,0.02287824,0.0002689778,0.00003077994,0.0007275298,0.00004904692,0.00001252066,0.00001906807,0.00004718665],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.5405378,"threshold_uncertainty_score":0.3981735,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2027176779","doi":"10.1038/bjc.2011.201","title":"XELOX vs FOLFOX-4 as first-line therapy for metastatic colorectal cancer: NO16966 updated results","year":2011,"lang":"en","type":"article","venue":"British Journal of Cancer","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":227,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"CancerCare Manitoba; St. Boniface Hospital","funders":"","keywords":"Folinic acid; Oxaliplatin; Medicine; Bevacizumab; Capecitabine; Internal medicine; FOLFOX; Colorectal cancer; Population; Placebo; Hazard ratio; Fluorouracil; Oncology; Neutropenia; Gastroenterology; Surgery; Chemotherapy; Cancer; Confidence interval; Pathology","retraction":null,"screen_n_in":null,"score":{"opus":0.04379543442494756,"gpt":0.3317247483501661,"spread":0.2879293139252185,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002753498,0.0002235845,0.0007540121,0.0001021571,0.0001980265,0.00003840382,0.0001407076,0.00006483773,0.0008632574],"category_scores_gemma":[0.0001333877,0.0001911734,0.000324712,0.0002192197,0.000107616,0.0001598613,0.00002646405,0.0002270516,0.000003776111],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0003200904,"about_ca_system_score_gemma":0.0005421924,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.005094838,"about_ca_topic_score_gemma":0.009926096,"domain_scores_codex":[0.9982457,0.00003456946,0.0007171286,0.0002545245,0.00038239,0.0003656815],"domain_scores_gemma":[0.998249,0.0000839099,0.0005156252,0.0001045586,0.0008411428,0.0002057755],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.07731897,0.001668047,0.01674323,0.0001664207,0.006369534,0.002100271,0.00300612,0.00003546742,0.0007106083,0.00003993864,0.06865785,0.8231835],"study_design_scores_gemma":[0.06036042,0.01949528,0.3954279,0.002206307,0.002356562,0.00349205,0.0005017766,0.00009566661,0.02576689,0.001062411,0.4884632,0.000771508],"study_design_candidate":"design_other","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9327781,0.06006806,0.0000510376,0.002281185,0.001064217,0.0008811821,0.0005280992,0.00002924444,0.002318853],"genre_scores_gemma":[0.9333563,0.06278714,0.0008947433,0.0008363639,0.0005948514,0.0002362091,0.00002243101,0.00004634591,0.001225653],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.822412,"threshold_uncertainty_score":0.9452063,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2135454464","doi":"10.1371/journal.pone.0047054","title":"The Prognostic Value of BRAF Mutation in Colorectal Cancer and Melanoma: A Systematic Review and Meta-Analysis","year":2012,"lang":"en","type":"review","venue":"PLoS ONE","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":220,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false},"ca_institutions":"Vancouver Coastal Health Research Institute; University of British Columbia; Vancouver Coastal Health","funders":"CIHR Skin Research Training Centre; Canadian Institutes of Health Research; Canadian Dermatology Foundation","keywords":"Colorectal cancer; Meta-analysis; Medicine; Oncology; Melanoma; Cancer; Mutation; Mutation testing; Value (mathematics); Internal medicine; Cancer research; Biology; Genetics; Statistics; Gene","retraction":null,"screen_n_in":null,"score":{"opus":0.1484729905950436,"gpt":0.3465267106802264,"spread":0.1980537200851828,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004401692,0.000267192,0.006377916,0.0001248997,0.00005448877,0.0000119512,0.00005023913,0.00007125661,0.00002601993],"category_scores_gemma":[0.0002790829,0.0001250001,0.0004798409,0.0005077617,0.00007827696,0.00002864955,0.00004992169,0.0001288721,0.000001559717],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0001048744,"about_ca_system_score_gemma":0.00008037468,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0001469655,"about_ca_topic_score_gemma":0.0004842756,"domain_scores_codex":[0.9983912,0.0002298196,0.000713929,0.0002325128,0.0002745879,0.0001579252],"domain_scores_gemma":[0.9985188,0.000657577,0.0004954051,0.0001708739,0.0001010826,0.00005625848],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","study_design_scores_codex":[0.000006967965,0.0002262284,0.000250876,0.749352,0.248018,0.00000605574,0.0001072338,1.231979e-8,9.667306e-8,0.00001684704,0.000001779337,0.002013889],"study_design_scores_gemma":[0.0001341511,0.0001595451,0.0004095978,0.05538969,0.9436461,0.00001398169,0.00001619696,0.000003818531,9.243055e-7,0.000003838813,0.0001245905,0.00009753365],"study_design_candidate":"meta_analysis","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.0007686097,0.9937062,1.659044e-7,0.0001849284,0.000006422365,0.005184234,0.00007055785,0.000007230798,0.00007171124],"genre_scores_gemma":[0.003985143,0.9914383,0.00003861436,0.00002934187,0.00001334921,0.004250158,0.00002523848,0.00001707502,0.0002027969],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.6956282,"threshold_uncertainty_score":0.5097356,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2068694673","doi":"10.2217/pgs.11.72","title":"Dihydropyrimidine Dehydrogenase Gene as a Major Predictor of Severe 5-Fluorouracil Toxicity","year":2011,"lang":"en","type":"review","venue":"Pharmacogenomics","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":214,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Child and Family Research Institute; University of British Columbia","funders":"","keywords":"Dihydropyrimidine dehydrogenase; Fluorouracil; Toxicity; Gene; Pharmacology; Chemistry; Cancer research; Medicine; Thymidylate synthase; Internal medicine; Biochemistry; Chemotherapy","retraction":null,"screen_n_in":null,"score":{"opus":0.0719621557198927,"gpt":0.3538005639990978,"spread":0.2818384082792051,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0001721824,0.0007597488,0.002825452,0.0002012241,0.0001103956,0.0000113043,0.0002844676,0.0002488878,0.001002965],"category_scores_gemma":[0.00005030038,0.0005785995,0.001071496,0.0002851565,0.0001343828,0.00005914652,0.0002808094,0.0003973967,0.0001768351],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0005920117,"about_ca_system_score_gemma":0.0007794275,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0001692645,"about_ca_topic_score_gemma":0.00001300538,"domain_scores_codex":[0.9975379,0.00008633544,0.0009735043,0.0006426734,0.0002778049,0.0004817502],"domain_scores_gemma":[0.9982674,0.0000936437,0.0006069136,0.0005118996,0.0001555048,0.0003646828],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.001107608,0.001354596,0.000116426,0.02516558,0.009648615,0.0005428991,0.0005533338,0.000001106097,0.0007452407,0.00005528167,0.002173429,0.9585359],"study_design_scores_gemma":[0.001998012,0.0006658666,0.000006831986,0.002085391,0.01345157,0.0009042913,0.00001258248,0.000007440145,0.003634783,0.00003233391,0.9766676,0.0005333116],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.01581659,0.9753886,0.0000033897,0.00001767336,0.0003895881,0.001931835,0.001484227,0.00008200035,0.004886046],"genre_scores_gemma":[0.002132787,0.994929,0.0003179318,0.0001203627,0.0005089117,0.0002935753,0.0003666403,0.0001377825,0.001193022],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.9744942,"threshold_uncertainty_score":0.9999102,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W1981284988","doi":"10.1016/j.ccr.2013.05.014","title":"A Genetic Progression Model of BrafV600E-Induced Intestinal Tumorigenesis Reveals Targets for Therapeutic Intervention","year":2013,"lang":"en","type":"article","venue":"Cancer Cell","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":214,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false},"ca_institutions":"","funders":"Deutsche Forschungsgemeinschaft; Helmholtz-Gemeinschaft; Partenariat Canadien Contre Le Cancer; Wellcome Trust","keywords":"Carcinogenesis; Cancer research; Colorectal cancer; Biology; MAPK/ERK pathway; Tumor progression; Somatic cell; Mutation; Hyperplasia; Cancer; Signal transduction; Bioinformatics; Medicine; Gene; Genetics; Endocrinology","retraction":null,"screen_n_in":null,"score":{"opus":0.0440716357610673,"gpt":0.3372972348395828,"spread":0.2932255990785155,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00004916245,0.0001394808,0.0002872575,0.00003390638,0.00005235364,0.000007866662,0.00005635563,0.00004010184,0.0001889429],"category_scores_gemma":[0.00001064601,0.0001002046,0.0001458208,0.00006621607,0.00003145301,0.00005108449,0.00002846781,0.00004332114,0.000004246414],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0001783955,"about_ca_system_score_gemma":0.0000751897,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0003586302,"about_ca_topic_score_gemma":0.00005792916,"domain_scores_codex":[0.9991888,0.00001507995,0.0002582736,0.0002174636,0.0001274341,0.0001929863],"domain_scores_gemma":[0.9993845,0.00002700239,0.0001401695,0.0001428821,0.0002396415,0.00006579243],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","study_design_scores_codex":[0.0006360623,0.0008933438,0.0430891,0.001537976,0.0002789659,0.000003495994,0.001137944,0.00009490104,0.501702,0.00002405893,0.001957491,0.4486447],"study_design_scores_gemma":[0.01119682,0.008859525,0.3062155,0.002174219,0.001500015,0.00001721108,0.0009574566,0.05168907,0.6125098,0.003289226,0.0008441092,0.0007470439],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9819919,0.01372716,0.001581579,0.0002859593,0.000161546,0.001439231,0.00001365956,0.00002912699,0.0007698354],"genre_scores_gemma":[0.9942701,0.0003799509,0.002554135,0.00009866172,0.00008602226,0.001418638,0.000006157522,0.00002281686,0.001163544],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.4478977,"threshold_uncertainty_score":0.4086225,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2123811123","doi":"10.1093/annonc/mdn370","title":"Capecitabine plus oxaliplatin (XELOX) versus 5-fluorouracil/folinic acid plus oxaliplatin (FOLFOX-4) as second-line therapy in metastatic colorectal cancer: a randomized phase III noninferiority study","year":2008,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":199,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Princess Margaret Cancer Centre; Ottawa Hospital","funders":"National Institute for Health and Care Research; Roche","keywords":"FOLFOX; Medicine; Oxaliplatin; Folinic acid; Internal medicine; Capecitabine; Irinotecan; Colorectal cancer; FOLFIRINOX; Neutropenia; Oncology; FOLFIRI; Population; Clinical endpoint; Fluorouracil; Surgery; Chemotherapy; Cancer; Randomized controlled trial","retraction":null,"screen_n_in":null,"score":{"opus":0.1341549568313934,"gpt":0.4386820001262048,"spread":0.3045270432948114,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.001337689,0.0006158305,0.004100292,0.0003817526,0.000242952,0.00001242636,0.0002268079,0.0002163588,0.001791222],"category_scores_gemma":[0.0006836801,0.0004828332,0.0005180115,0.0006552096,0.0005990844,0.0001687979,0.0001444221,0.0005436183,0.00002530145],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0006259326,"about_ca_system_score_gemma":0.00228254,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.005443932,"about_ca_topic_score_gemma":0.01299669,"domain_scores_codex":[0.9954724,0.0007596433,0.001685662,0.0007386296,0.000576159,0.0007675094],"domain_scores_gemma":[0.9963973,0.001620311,0.000771168,0.0003957932,0.0005473096,0.0002681809],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.89458,0.008218027,0.004272386,0.00007519769,0.005103199,0.001935288,0.02174111,0.00009025665,0.001964812,0.00007010716,0.001034173,0.06091541],"study_design_scores_gemma":[0.9059877,0.06813596,0.009970656,0.00008038848,0.0007792264,0.0001641189,0.003607664,0.00086878,0.006465717,0.0001084464,0.003279195,0.0005521089],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9810724,0.006511953,0.00001061847,0.002082907,0.0007667238,0.004340535,0.0001380876,0.00007178966,0.005004937],"genre_scores_gemma":[0.9897512,0.006925115,0.0002560623,0.0006126897,0.0002684639,0.001425064,0.00008451589,0.00005099786,0.0006259396],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.0603633,"threshold_uncertainty_score":0.9997624,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2138075845","doi":"10.1093/annonc/mdp533","title":"Bevacizumab combined with chemotherapy for patients with advanced colorectal cancer: a systematic review","year":2009,"lang":"en","type":"review","venue":"Annals of Oncology","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":188,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Ottawa Regional Cancer Foundation; Ottawa Hospital; Cancer Care Ontario; McMaster University; London Health Sciences Centre","funders":"","keywords":"Bevacizumab; Medicine; Internal medicine; Colorectal cancer; Chemotherapy; Oncology; Hazard ratio; Irinotecan; Chemotherapy regimen; Adverse effect; Regimen; Cetuximab; Surgery; Gastrointestinal perforation; Cancer; Confidence interval","retraction":null,"screen_n_in":null,"score":{"opus":0.05019558973070794,"gpt":0.4076534941457312,"spread":0.3574579044150232,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0001790571,0.0005757582,0.007606749,0.0001246856,0.00007047411,0.000004883158,0.0001606631,0.0002056242,0.00002904423],"category_scores_gemma":[0.0001020382,0.0003035043,0.0005150555,0.0003483466,0.0001254965,0.0000406918,0.00002215479,0.0001795233,0.00000255437],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0003120761,"about_ca_system_score_gemma":0.0009980864,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00001353286,"about_ca_topic_score_gemma":0.00008218321,"domain_scores_codex":[0.9977964,0.000115466,0.0009290715,0.0004661164,0.0003011807,0.0003918181],"domain_scores_gemma":[0.9970692,0.00033284,0.001327437,0.0003346081,0.0008175467,0.0001183316],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","study_design_scores_codex":[0.002569987,0.000769423,0.00001734291,0.5050597,0.002288222,0.00001216953,0.00004048609,5.310268e-8,1.895365e-8,0.00001109979,0.001048133,0.4881833],"study_design_scores_gemma":[0.006053525,0.07225103,0.00007381521,0.5241675,0.009166577,0.00003271919,0.00001067594,2.792229e-7,0.000001707724,0.000006526563,0.3879342,0.0003014382],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.0001782086,0.9836542,0.000001981958,0.0008584568,0.00007007837,0.01422996,0.000174966,0.00003282922,0.0007993358],"genre_scores_gemma":[0.0001379639,0.9923073,0.0002882308,0.001223161,0.00004146971,0.005502677,0.0002396481,0.00006543208,0.0001941208],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.4878819,"threshold_uncertainty_score":0.9999417,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W1831535185","doi":"","title":"Methylenetetrahydrofolate reductase polymorphism in advanced colorectal cancer: a novel genomic predictor of clinical response to fluoropyrimidine-based chemotherapy.","year":2003,"lang":"en","type":"article","venue":"PubMed","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":183,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"McGill University","funders":"","keywords":"Methylenetetrahydrofolate reductase; Thymidylate synthase; Colorectal cancer; Internal medicine; Genotyping; Allele; Odds ratio; Genotype; Oncology; Medicine; Gastroenterology; Fluorouracil; Biology; Chemotherapy; Cancer; Genetics; Gene","retraction":null,"screen_n_in":null,"score":{"opus":0.03817776695316645,"gpt":0.3224104275268397,"spread":0.2842326605736733,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001048271,0.0002717562,0.0008829846,0.0002645021,0.00004561096,0.000007142486,0.0001103149,0.0001251228,0.00006500771],"category_scores_gemma":[0.0009009501,0.0002316751,0.0002218026,0.0005264702,0.0001248323,0.00004448659,0.00002950775,0.0002018363,0.000002453472],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0004484954,"about_ca_system_score_gemma":0.0004705271,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0002404145,"about_ca_topic_score_gemma":0.0001250663,"domain_scores_codex":[0.997665,0.0001737537,0.0007961834,0.0005351327,0.0002854013,0.0005444755],"domain_scores_gemma":[0.9987404,0.000320171,0.0001941882,0.0002997948,0.0001009722,0.0003444271],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","study_design_scores_codex":[0.1373506,0.003286942,0.3125262,0.0001389554,0.001043042,0.0001366357,0.001141839,0.000346239,0.3201392,0.00003761032,0.0006140216,0.2232387],"study_design_scores_gemma":[0.01277518,0.000954447,0.8905604,0.00004947163,0.0001200092,0.000008292693,0.00005290135,0.00006452025,0.09036566,0.00001032705,0.004835129,0.0002035931],"study_design_candidate":"observational","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9920054,0.002387681,0.0000189949,0.002116,0.0004891498,0.002352678,0.0001262656,0.00004778807,0.0004560066],"genre_scores_gemma":[0.9941139,0.0002596039,0.001680359,0.000581279,0.00008564334,0.00291176,0.000007003424,0.0000456619,0.0003147371],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.5780343,"threshold_uncertainty_score":0.9447438,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2006709656","doi":"10.1038/sj.bjc.6603055","title":"Phase II study of erlotinib (OSI-774) in patients with metastatic colorectal cancer","year":2006,"lang":"en","type":"article","venue":"British Journal of Cancer","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":178,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"University of Toronto; Princess Margaret Cancer Centre","funders":"National Cancer Institute","keywords":"Erlotinib; Medicine; Rash; Internal medicine; Colorectal cancer; Cancer; Epidermal growth factor receptor; Adverse effect; Oncology; Gastroenterology; Progressive disease; Phases of clinical research; Chemotherapy","retraction":null,"screen_n_in":null,"score":{"opus":0.01175758132970531,"gpt":0.3057892982061223,"spread":0.294031716876417,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001274362,0.0001498688,0.0006775985,0.0001299144,0.00008507067,0.00001478422,0.00007001608,0.00002410059,0.0002112678],"category_scores_gemma":[0.00002085339,0.0001220967,0.00008411643,0.0002947879,0.0000694947,0.0001179084,0.00002989827,0.0001907404,2.228649e-7],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0002940626,"about_ca_system_score_gemma":0.000255726,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_topic_score_codex":0.01048224,"about_ca_topic_score_gemma":0.04126491,"domain_scores_codex":[0.9984251,0.00004075853,0.0005934692,0.0001585002,0.0005417043,0.0002404622],"domain_scores_gemma":[0.9989164,0.00002660274,0.0004266679,0.0000618443,0.0004946192,0.0000738016],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.007511218,0.01605835,0.8360327,0.00006363731,0.0009202138,0.0006452709,0.0009035139,0.0001782593,0.0001098948,0.000001918653,0.00126462,0.1363103],"study_design_scores_gemma":[0.04789735,0.01959071,0.9294296,0.0006899351,0.0006365983,0.00007099998,0.0004775191,0.000006137495,0.0003366919,0.0000100034,0.0007307071,0.0001237253],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9897324,0.008930116,0.000001714616,0.00008516933,0.0001966018,0.000646988,0.00008576553,0.00000523568,0.0003159553],"genre_scores_gemma":[0.9990126,0.0004704557,0.00008552416,0.00004554303,0.0001250432,0.00007561305,0.000004096174,0.00002143441,0.0001596973],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.1361866,"threshold_uncertainty_score":0.996107,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2125955619","doi":"10.1158/1078-0432.ccr-13-0606","title":"<i>PIK3CA, BRAF</i>, and PTEN Status and Benefit from Cetuximab in the Treatment of Advanced Colorectal Cancer—Results from NCIC CTG/AGITG CO.17","year":2013,"lang":"en","type":"article","venue":"Clinical Cancer Research","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":165,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Ottawa Hospital","funders":"","keywords":"PTEN; Cetuximab; Colorectal cancer; Medicine; Oncology; Internal medicine; Biomarker; Immunohistochemistry; Cancer; Tissue microarray; Cancer research; Biology","retraction":null,"screen_n_in":null,"score":{"opus":0.1313937576986007,"gpt":0.4804904139291039,"spread":0.3490966562305032,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004633398,0.0002746926,0.0009225127,0.0001065993,0.0001813031,0.00006055597,0.000162417,0.0001623526,0.0003780501],"category_scores_gemma":[0.0002729266,0.0001671931,0.0001216963,0.0003281461,0.0008669728,0.0001066751,0.0001142171,0.0003726146,0.00001136653],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0004321097,"about_ca_system_score_gemma":0.000317735,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_topic_score_codex":0.1026393,"about_ca_topic_score_gemma":0.03468513,"domain_scores_codex":[0.9969009,0.0002094879,0.0007682614,0.0008026083,0.000662165,0.0006566152],"domain_scores_gemma":[0.9955541,0.003269322,0.0001467595,0.000410333,0.00031165,0.0003078702],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.00993727,0.001390452,0.5475085,0.00003435946,0.000532944,0.00005851481,0.00534688,0.00000626099,0.0007202106,0.00001570517,0.001783934,0.432665],"study_design_scores_gemma":[0.01585168,0.004650081,0.9629371,0.0001897806,0.0001313146,0.000001351957,0.001897656,0.000122364,0.0008384095,0.0009704268,0.01224417,0.000165704],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9543035,0.03712135,2.472525e-7,0.003876204,0.0001521492,0.001701121,0.00144808,0.00001741979,0.00137992],"genre_scores_gemma":[0.9237413,0.07387611,0.00006753152,0.0002599591,0.0003221445,0.001099038,0.0001114584,0.00002466048,0.0004978426],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.4324993,"threshold_uncertainty_score":0.9829293,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2140510616","doi":"10.1093/annonc/mdm399","title":"An open-label, single-arm study assessing safety and efficacy of panitumumab in patients with metastatic colorectal cancer refractory to standard chemotherapy","year":2007,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":155,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Essar Steel Algoma (Canada); Sault Area Hospital","funders":"Amgen","keywords":"Panitumumab; Medicine; Internal medicine; Colorectal cancer; Adverse effect; Refractory (planetary science); Oncology; Phases of clinical research; Response Evaluation Criteria in Solid Tumors; Clinical endpoint; Progressive disease; Chemotherapy; Progression-free survival; Surgery; Cancer; Clinical trial; Cetuximab","retraction":null,"screen_n_in":null,"score":{"opus":0.08917227959175789,"gpt":0.4430520888022599,"spread":0.353879809210502,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00054753,0.000163252,0.0008485031,0.0001570942,0.00005485808,0.00001097536,0.00009485603,0.00004521459,0.00003676038],"category_scores_gemma":[0.00007137239,0.0001191351,0.00001591776,0.0002806681,0.000123896,0.0001318039,0.00006481751,0.0001042576,1.906379e-7],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0002316458,"about_ca_system_score_gemma":0.0002605237,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0006668682,"about_ca_topic_score_gemma":0.004000579,"domain_scores_codex":[0.9986719,0.00009584122,0.0004461563,0.0002857516,0.000245908,0.0002544089],"domain_scores_gemma":[0.9989079,0.0002255662,0.0002346221,0.0001457585,0.0003705168,0.0001156325],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"observational","study_design_scores_codex":[0.06085676,0.02603148,0.4513581,0.00003974575,0.0005973779,0.00005139331,0.005440659,0.000005587634,0.001622146,0.000007396064,0.00004685553,0.4539425],"study_design_scores_gemma":[0.02361522,0.1328128,0.8390162,0.00009500994,0.0001091513,0.000001607755,0.001529259,0.000001612063,0.001675317,0.000006583448,0.001035257,0.0001020046],"study_design_candidate":"observational","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9965668,0.0002825448,0.00001863162,0.0003735023,0.00005534385,0.00147602,0.00003261329,0.000008277983,0.001186297],"genre_scores_gemma":[0.9985412,0.0001010432,0.0008888998,0.0003854524,0.00001637134,0.00002659272,0.000008214613,0.00001960624,0.00001258098],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.4538405,"threshold_uncertainty_score":0.4858187,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2114578638","doi":"10.1007/s00520-009-0744-x","title":"A proposed EGFR inhibitor dermatologic adverse event-specific grading scale from the MASCC skin toxicity study group","year":2010,"lang":"en","type":"article","venue":"Supportive Care in Cancer","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":151,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Ontario Institute for Cancer Research","funders":"Robert H. Lurie Comprehensive Cancer Center; Amgen; Dermatology Foundation","keywords":"Medicine; Common Terminology Criteria for Adverse Events; Grading (engineering); Pharmacovigilance; Adverse effect; Dermatology; MedDRA; Internal medicine","retraction":null,"screen_n_in":null,"score":{"opus":0.01789740288903616,"gpt":0.3095338887530041,"spread":0.291636485863968,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001562252,0.0002716263,0.0004652342,0.0000650545,0.0001946838,0.00002013769,0.0001364024,0.00009674346,0.0006392414],"category_scores_gemma":[0.00005466242,0.0001688469,0.0001566686,0.0002981108,0.0001605412,0.0001063354,0.0001130728,0.0004715739,0.00001657752],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0005817269,"about_ca_system_score_gemma":0.000183907,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001986619,"about_ca_topic_score_gemma":0.05629616,"domain_scores_codex":[0.9982679,0.000101855,0.0003881359,0.0005215161,0.0003492966,0.0003712512],"domain_scores_gemma":[0.999112,0.0001260726,0.0001362377,0.0003348846,0.0001867834,0.0001040231],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.0006474373,0.0005827424,0.9606264,0.00002747768,0.0001573804,0.0002907479,0.01940718,0.000001103937,0.002141402,0.00001272949,0.002257931,0.01384753],"study_design_scores_gemma":[0.003807276,0.0008135393,0.920132,0.0001247731,0.0001598735,0.00001092529,0.05773952,0.000007454555,0.006933104,0.0000584908,0.009970256,0.0002427678],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9924765,0.002269878,0.00000566334,0.001167661,0.001162302,0.001926033,0.0001674953,0.00005088681,0.0007736128],"genre_scores_gemma":[0.9981171,0.0002058351,0.00007954351,0.0004457205,0.0004135301,0.0005714482,0.00004787841,0.00002584666,0.00009307234],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.05430954,"threshold_uncertainty_score":0.960924,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W1488835948","doi":"10.1038/nrc1047","title":"Improving the evaluation of new cancer treatments: challenges and opportunities","year":2003,"lang":"en","type":"review","venue":"Nature reviews. Cancer","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":149,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false},"ca_institutions":"","funders":"National Cancer Institute; McGill University","keywords":"Clinical trial; Medicine; Cancer; Cancer drugs; Intensive care medicine; Computational biology; Biology; Internal medicine","retraction":null,"screen_n_in":null,"score":{"opus":0.3441167785904543,"gpt":0.471561718432465,"spread":0.1274449398420108,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0007795001,0.0005790713,0.002767082,0.0001086152,0.00009813477,0.00001420566,0.000115099,0.0004205707,0.0003064114],"category_scores_gemma":[0.0001453085,0.0002801445,0.0005240376,0.0001744325,0.0001017152,0.0000612607,0.00005696663,0.0005702521,0.000002283912],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0008194196,"about_ca_system_score_gemma":0.001840421,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0002877358,"about_ca_topic_score_gemma":0.0004292978,"domain_scores_codex":[0.9976314,0.0003440164,0.0006725002,0.0005097167,0.0005861276,0.0002562154],"domain_scores_gemma":[0.9982046,0.0001138949,0.0007874016,0.0004680842,0.0003081298,0.0001178813],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.00001269133,0.00003696442,0.00000312401,0.01918594,0.001200748,0.000002720511,0.0002622005,5.70846e-8,1.207269e-7,0.00008662014,0.00251954,0.9766893],"study_design_scores_gemma":[0.0006868466,0.0001334562,0.0000510427,0.02826974,0.02219382,0.00002662928,0.00007052107,0.000001322889,9.582616e-7,0.00002157468,0.9483334,0.0002106946],"study_design_candidate":"design_other","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.000006602679,0.9922097,2.651917e-7,0.0006603951,0.0005777379,0.003820663,0.00008347091,0.0000143607,0.0026268],"genre_scores_gemma":[0.000007453121,0.9936475,0.0000423551,0.000291321,0.0004650315,0.002722344,0.0000337246,0.00005185379,0.00273845],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.9764786,"threshold_uncertainty_score":0.9999651,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W1484628085","doi":"10.1054/bjoc.1999.0964","title":"Thymidilate synthase and p53 primary tumour expression as predictive factors for advanced colorectal cancer patients","year":2000,"lang":"en","type":"article","venue":"British Journal of Cancer","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":149,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Queen's University","funders":"","keywords":"Colorectal cancer; Immunohistochemistry; Medicine; Thymidylate synthase; Chemotherapy; Internal medicine; Hazard ratio; Oncology; Cancer; Immunostaining; Retrospective cohort study; Confidence interval; Gastroenterology; Pathology; Fluorouracil","retraction":null,"screen_n_in":null,"score":{"opus":0.007577149139346323,"gpt":0.2761854846126583,"spread":0.268608335473312,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00006676446,0.000183704,0.0005171971,0.00005367131,0.0001877997,0.00003439318,0.00006014336,0.00006796694,0.0005045881],"category_scores_gemma":[0.00007485702,0.0001550218,0.000153262,0.00008252598,0.0000894777,0.0002455757,0.00002343102,0.0001856495,6.286824e-7],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0003701382,"about_ca_system_score_gemma":0.0002482017,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0003577217,"about_ca_topic_score_gemma":0.0002456339,"domain_scores_codex":[0.9987789,0.00002456873,0.0003695788,0.0002220549,0.0003436593,0.0002611842],"domain_scores_gemma":[0.9990522,0.00008618898,0.0002389993,0.0000453504,0.0003729907,0.000204313],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"observational","study_design_scores_codex":[0.01871248,0.0007394577,0.1725476,0.0002193986,0.0007972091,0.0002494644,0.001276701,0.00008737039,0.008955728,9.884842e-7,0.004028103,0.7923855],"study_design_scores_gemma":[0.00969561,0.004078597,0.9507122,0.002343367,0.0004945602,0.0001969493,0.0002483901,0.0000144928,0.02033684,0.0000573297,0.01158207,0.0002395921],"study_design_candidate":"observational","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9666519,0.03093198,0.00000464337,0.0001549896,0.0003707746,0.0005902979,0.000373984,0.00001499564,0.0009064589],"genre_scores_gemma":[0.9705874,0.02804381,0.0001161445,0.0001955115,0.0002551772,0.000137565,0.00001436142,0.00002969513,0.000620313],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.7921459,"threshold_uncertainty_score":0.6321605,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W1996283150","doi":"10.1016/j.ejca.2005.11.014","title":"Pooled safety analysis of BAY 43-9006 (sorafenib) monotherapy in patients with advanced solid tumours: Is rash associated with treatment outcome?","year":2006,"lang":"en","type":"review","venue":"European Journal of Cancer","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":149,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Hamilton Regional Laboratory Medicine Program","funders":"Bayer Corporation","keywords":"Sorafenib; Rash; Medicine; Toxicity; Internal medicine; Adverse effect; Pharmacology; Gastroenterology; Oncology; Surgery; Hepatocellular carcinoma","retraction":null,"screen_n_in":null,"score":{"opus":0.02424993816082504,"gpt":0.335736719819994,"spread":0.3114867816591689,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0003336962,0.0006745958,0.004666337,0.0007956956,0.00006077069,0.0000200472,0.0001808421,0.00006386199,0.0001709218],"category_scores_gemma":[0.00002858553,0.0003580129,0.0009675308,0.001384806,0.00009492663,0.00008661801,0.00002436329,0.0003382872,0.000001896743],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001853346,"about_ca_system_score_gemma":0.0004597418,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00008406512,"about_ca_topic_score_gemma":0.000856549,"domain_scores_codex":[0.9964176,0.0003943239,0.001723469,0.0003845016,0.0007195881,0.0003604597],"domain_scores_gemma":[0.9960769,0.0001091189,0.002723591,0.0003192522,0.0006268165,0.0001442944],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"observational","study_design_scores_codex":[0.002949345,0.001187101,0.2973254,0.0003886969,0.03129982,0.000335765,0.0004180648,0.0003522408,2.322361e-7,4.117614e-7,0.0001651591,0.6655778],"study_design_scores_gemma":[0.0196022,0.006846292,0.6598191,0.01230573,0.04885167,0.000006862455,0.00004454494,0.000004262347,0.000003899018,3.404021e-7,0.2520128,0.000502288],"study_design_candidate":"observational","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.04476461,0.952136,0.00001555359,0.0001022054,0.0001204748,0.0009448171,0.0004746428,0.00001321726,0.001428509],"genre_scores_gemma":[0.04384193,0.9543254,0.0001220216,0.00009461762,0.000109783,0.00002531439,0.0001457656,0.0001320167,0.001203134],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.6650755,"threshold_uncertainty_score":0.9998872,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2169034512","doi":"10.1186/1476-4598-13-135","title":"Analyses of clinicopathological, molecular, and prognostic associations of KRAS codon 61 and codon 146 mutations in colorectal cancer: cohort study and literature review","year":2014,"lang":"en","type":"article","venue":"Molecular Cancer","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":147,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false},"ca_institutions":"","funders":"Damon Runyon Cancer Research Foundation; Gary Bennett Family Fund; National Cancer Institute; National Institutes of Health; Harvard University; Entertainment Industry Foundation","keywords":"KRAS; Microsatellite instability; Colorectal cancer; Biology; Oncology; Cancer research; Internal medicine; Hazard ratio; Cancer; Mutation; Genetics; Medicine; Allele; Gene; Microsatellite","retraction":null,"screen_n_in":null,"score":{"opus":0.03177955794768534,"gpt":0.3868421815313034,"spread":0.3550626235836181,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002699815,0.0001697059,0.0007505133,0.00009676467,0.00005915788,0.00001592208,0.00003318057,0.00006992105,0.00001290012],"category_scores_gemma":[0.0004038764,0.0001316727,0.00006069363,0.0003833136,0.0001911985,0.0000350537,0.00005734901,0.0001296506,8.547988e-8],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00006804296,"about_ca_system_score_gemma":0.00008593406,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0006087429,"about_ca_topic_score_gemma":0.0009866563,"domain_scores_codex":[0.9987425,0.0001736694,0.0003942892,0.0003306523,0.0002164139,0.0001425141],"domain_scores_gemma":[0.9992533,0.0001297661,0.0002111589,0.0001141647,0.0002248649,0.0000667171],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.00007426591,0.0003061317,0.9840006,0.0005960664,0.0003179728,0.00007707563,0.0006432341,0.000009656723,0.009770301,0.00002796848,0.00003454329,0.004142197],"study_design_scores_gemma":[0.001499066,0.001197641,0.9910324,0.001605595,0.001481024,0.00001226751,0.0001025658,0.00007393643,0.002784959,0.00004304703,0.00004962564,0.0001178523],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.8501542,0.1479244,0.00001772514,0.00039802,0.00002785681,0.001224618,0.00008679887,0.000008970447,0.000157455],"genre_scores_gemma":[0.965492,0.03362873,0.0001322201,0.0002485585,0.00001021935,0.0004334385,0.00003030821,0.00001228155,0.00001222226],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.1153378,"threshold_uncertainty_score":0.5369459,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2079491773","doi":"10.1007/s10238-007-0145-8","title":"Uncovering Pandora’s vase: the growing problem of new toxicities from novel anticancer agents. The case of sorafenib and sunitinib","year":2007,"lang":"en","type":"review","venue":"Clinical and Experimental Medicine","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":146,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"University Hospital Foundation","funders":"","keywords":"Sorafenib; Sunitinib; Medicine; Rash; Hematology; Pharmacology; Cancer; Internal medicine; Skin cancer; Dermatology; Oncology","retraction":null,"screen_n_in":null,"score":{"opus":0.2324804966332922,"gpt":0.4766617285255226,"spread":0.2441812318922304,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005294283,0.000362951,0.002215265,0.00005426059,0.0001382173,0.000008180274,0.0001053838,0.0001537474,0.0001196274],"category_scores_gemma":[0.000133416,0.0001553094,0.000263822,0.0001623861,0.001562807,0.00005426328,0.0002228095,0.0003565575,5.576902e-7],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0000396348,"about_ca_system_score_gemma":0.0001332153,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.003222947,"about_ca_topic_score_gemma":0.00008728146,"domain_scores_codex":[0.9978456,0.00007694382,0.001251844,0.0003706069,0.0002380305,0.0002169041],"domain_scores_gemma":[0.9976239,0.001446244,0.0004266644,0.0002829689,0.00004951071,0.0001706959],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.000506058,0.0003355331,0.0003550145,0.002579191,0.001631894,0.0003292538,0.002828938,1.073628e-7,0.00004565189,0.000246158,0.0008997017,0.9902425],"study_design_scores_gemma":[0.01254228,0.005304038,0.0008039679,0.03809906,0.007857494,0.001481682,0.02112415,0.000008795081,0.0004883751,0.0002437942,0.911513,0.0005334108],"study_design_candidate":"design_other","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.06474226,0.9327635,0.00000675242,0.0005311127,0.0003098497,0.0008974585,0.00007652131,0.0000106606,0.0006618781],"genre_scores_gemma":[0.05457675,0.9436876,0.0001492288,0.0004881729,0.0007603148,0.00003891701,0.00003486799,0.0000282658,0.0002358553],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.9897091,"threshold_uncertainty_score":0.6333332,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W1510315517","doi":"10.1002/ijc.29025","title":"Clinical importance of risk variants in the dihydropyrimidine dehydrogenase gene for the prediction of early‐onset fluoropyrimidine toxicity","year":2014,"lang":"en","type":"article","venue":"International Journal of Cancer","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":145,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Child and Family Research Institute; University of British Columbia","funders":"Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung; National Science Foundation","keywords":"DPYD; Medicine; Toxicity; Internal medicine; Dihydropyrimidine dehydrogenase; Relative risk; Retrospective cohort study; Prospective cohort study; Gastroenterology; Pharmacogenetics; Surgery; Chemotherapy; Oncology; Fluorouracil; Confidence interval; Biology; Genetics; Genotype; Gene; Thymidylate synthase","retraction":null,"screen_n_in":null,"score":{"opus":0.03641762488755532,"gpt":0.3689768865698564,"spread":0.3325592616823011,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001003184,0.00009374446,0.000338336,0.00007431521,0.00003610942,0.000006978496,0.0002372062,0.00004299486,0.00004455164],"category_scores_gemma":[0.0005645351,0.00004779962,0.0002397624,0.00009435769,0.0001168869,0.00006319542,0.00002890554,0.0001757362,2.20173e-7],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00009574919,"about_ca_system_score_gemma":0.0001246558,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0002534728,"about_ca_topic_score_gemma":0.000403642,"domain_scores_codex":[0.9984213,0.00008293675,0.0008072646,0.0001034124,0.0004871681,0.00009797976],"domain_scores_gemma":[0.9977714,0.0006915778,0.0007804703,0.000138962,0.0005816918,0.00003589106],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.004214465,0.0004455988,0.9717984,0.00001539343,0.001250223,0.00001407029,0.0005959475,0.0002878379,0.001589974,0.00009613799,0.0008370738,0.01885487],"study_design_scores_gemma":[0.003713477,0.001182589,0.983197,0.0001381438,0.0004691474,0.00005400404,0.0000878645,0.001851147,0.007470377,0.000639069,0.001154281,0.00004291237],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9936194,0.002427027,0.0009803843,0.001681553,0.0007538296,0.0002333197,0.0002239314,0.000002221692,0.00007831788],"genre_scores_gemma":[0.9953566,0.003344581,0.0002775202,0.0002378397,0.0007339251,0.00002409318,0.000005010158,0.000008005295,0.00001237736],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.01881196,"threshold_uncertainty_score":0.1949212,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2147718573","doi":"10.1093/jnci/djp232","title":"Prospective Cost-Effectiveness Analysis of Cetuximab in Metastatic Colorectal Cancer: Evaluation of National Cancer Institute of Canada Clinical Trials Group CO.17 Trial","year":2009,"lang":"en","type":"article","venue":"JNCI Journal of the National Cancer Institute","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":141,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":true},"ca_institutions":"McMaster University; Niagara Health System; Ottawa Hospital; Health Sciences Centre; Princess Margaret Cancer Centre; Queen Elizabeth II Health Sciences Centre; Queen's University; Juravinski Cancer Centre; Dr. H. Bliss Murphy Cancer Centre; Sunnybrook Health Science Centre; University of Ottawa; Hamilton Health Sciences; Dalhousie University; University of Toronto; Ontario Institute for Cancer Research","funders":"","keywords":"Cetuximab; Colorectal cancer; Medicine; Oncology; Clinical trial; Internal medicine; Cancer","retraction":null,"screen_n_in":null,"score":{"opus":0.2580697799418732,"gpt":0.5230566580323922,"spread":0.264986878090519,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.008215754,0.0002484478,0.002063372,0.0005898631,0.0001077136,0.000009702815,0.000243813,0.00009600732,0.0001369898],"category_scores_gemma":[0.004513904,0.0001666999,0.0007550175,0.00167752,0.0003207514,0.0003142375,0.00003326576,0.0003617938,6.381807e-8],"about_ca_system_candidate":true,"about_ca_system_consensus":true,"about_ca_system_score_codex":0.005445184,"about_ca_system_score_gemma":0.01707928,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_topic_score_codex":0.04376476,"about_ca_topic_score_gemma":0.3425545,"domain_scores_codex":[0.9929063,0.0008050824,0.00236997,0.0002796632,0.003428401,0.0002105255],"domain_scores_gemma":[0.9906011,0.000830402,0.002958878,0.0001098769,0.005399418,0.0001003495],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.2040123,0.005291331,0.3491307,0.0003526445,0.04096589,0.00002848323,0.00149845,0.3390707,0.005337964,0.002222822,0.00552193,0.04656683],"study_design_scores_gemma":[0.06130864,0.001292168,0.9204647,0.0005868406,0.007123664,0.00001050208,0.0000756302,0.00243227,0.00462156,0.0008406944,0.001063202,0.0001801614],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9886962,0.002667891,0.00003006492,0.001010167,0.00292782,0.002414735,0.001247128,0.000003062805,0.001002916],"genre_scores_gemma":[0.9980709,0.0006476017,0.00008979017,0.0001882039,0.0005962609,0.0003326833,0.00002972301,0.000008880363,0.0000359334],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.571334,"threshold_uncertainty_score":0.9983727,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null}]}